

**ALIREZA MINAGAR, MD, MBA, MS (Bioinformatics)
Software Engineer**

(318) 288-2118 | aminagar@gmail.com

Based at Shreveport, Louisiana, USA

www.linkedin.com/in/alireza-minagar-md-mba-ms-biotech-bioinformatics-b450aa173/

<https://github.com/aliminagar>

<https://perfect-strokes.netlify.app/>

https://medium.com/@aminagar_38889

Alireza Minagar, MD, MBA, MS (Bioinformatics)

Senior Medical Writer & Scientific Consultant | Neurologist | Neuroimmunologist | Bioinformatics

Scientist | Software Engineer | Clinical Research Leader | Medical Educator

Founder & Principal Consultant, Perfect Strokes LLC (2021–Present)

Shreveport, LA, USA

Professional Summary

I currently serve as **Senior Medical Writer and Scientific Consultant** at *Perfect Strokes LLC*, where I provide high-level strategic and scientific writing services to pharmaceutical and biotechnology companies. My work encompasses **clinical trial documentation, regulatory submissions, scientific publications, and technical consultation** across multiple therapeutic domains.

As a **neurologist and neuroimmunologist** with over **30 years of experience** in academic medicine, clinical research, and neuroscience education. As **Professor and Chairman** of the Department of Neurology at Louisiana State University Health Sciences Center (LSUHSC) in Shreveport, I directed departmental strategy, faculty development, and institutional partnerships. I also **founded and led the LSUHSC Primary Stroke Center** and served as a **Board Member of the Center for Cardiovascular Diseases and Sciences**, fostering interdisciplinary research between neurology and vascular medicine.

A passionate and lifelong educator, I have **dedicated over three decades** to the **training, mentorship, and professional development** of **medical students, neurology residents, and clinical fellows**. Through structured teaching, bedside instruction, academic advising, and research collaboration, I have **nurtured generations of physicians and neuroscientists**, many of whom now hold leadership positions in academic institutions, clinical practice, and research centers. My teaching philosophy is grounded in a commitment to **academic rigor, intellectual curiosity, and humanistic care**, establishing a lasting legacy of excellence in neurological education.

Alongside my clinical career, I hold an **MBA** and a **master's in bioinformatics**, equipping me with a multidisciplinary skill set at the intersection of medicine, computational science, and data-driven innovation. As a **Bioinformatics Scientist and Software Engineer**, I work with tools and platforms that support **precision medicine, systems biology, and AI-powered diagnostics**, bringing a unique perspective to modern biomedical challenges.

With over **two decades of experience** as a **Principal Investigator**, I have led numerous clinical trials and translational research initiatives. My responsibilities have included drafting successful **grant proposals**, designing and submitting **clinical protocols**, overseeing **IRB submissions**, compiling **regulatory documentation**, and preparing **clinical trial reports**. In addition, I have worked extensively as a **medical writer, editor, and ghostwriter**, producing high-impact scientific manuscripts, review articles, and conference presentations for global audiences.

Education & Training

1989	“O” Level Diploma in English Language, London University,
1984-1991	M.D., Tehran University of Medical Sciences
1993	Certificate of Proficiency in English, Cambridge University
2017-2019	Master of Business Administration (MBA) from Louisiana State University in Shreveport, LA
2023	Artificial Intelligence and Machine Learning Univ. Texas Austin TX, USA
2021-2023	Master of Biotechnology-Bioinformatics University of Maryland Global Campus
2024-2025	Master of Software Engineering (pending graduation) University of Maryland Global Campus

Academic Appointments & Leadership

- **Professor & Chairman**, Department of Neurology
LSU Health Sciences Center – Shreveport, LA | Dec 2001 – Oct 2020
 - Joined the department in 2001; promoted to full Professor and later Chairman (2014–2018).
 - **Director**, Neuroscience Course (2014–2017):
 - Designed curriculum integrating neurology, neuroimmunology, neuroimaging, psychiatry, and neurophysiology.
 - Led CME and Grand Rounds programs for attending physicians.
 - Supervised the education of medical students, residents, and fellows with an emphasis on clinical applications of neuroscience.
-

Research Leadership & Clinical Trials

- **Principal Investigator (PI) | 2002–2018**
 - Led multiple investigator-initiated and industry-sponsored clinical trials (Serono, Biogen Idec, Bayer).
 - Responsible for:
 - Protocol development, regulatory submissions, safety monitoring, and IRB reporting.
 - Authoring grant applications, budgets, and final publications.
 - Collaborating with pharma and biotech companies for execution of research strategies.
- **Key Research Projects:**
 - **Serono-Pfizer, Inc. (2003–2009)**
 - \$62,500 Award: Soluble HLA molecules in MS as biomarkers of therapeutic response.
 - Collaborators: Irena Adamashvili, PhD; Roger E. Kelley, MD; Stephen Jaffe, MD.

- **Biogen Idec, Inc. (2004–2008)**
 - \$250,000 Award: Combination therapy with IFN- β -1a and doxycycline for MS.
 - Collaborators: J. Steven Alexander, PhD; Laura Warren, MS.
 - **Bayer Pharmaceuticals (2004–2006)**
 - \$150,000 Award: Proteomic analysis of IFN- β -1b effects on cerebral endothelial cells and MMPs.
 - Collaborators: J. Steven Alexander, PhD; Laura Warren, MS.
 - **Regulatory & Compliance Expertise**
 - Extensive experience submitting protocols to IRBs and global regulatory authorities.
 - Reviewed clinical trial safety narratives, IND updates, SAPs, and ensured adherence to GCP, SOPs, and industry best practices.
-

Medical Writing & Editorial Work

- **Senior Medical Writer & Editor – Elsevier & Springer (2005–2020)**
 - Led book projects and managed all editorial workflows.
 - Tasks included:
 - Authoring, revising, and finalizing manuscripts.
 - Coordinating contributor timelines and resource planning.
 - Ensuring scientific accuracy, compliance, and stylistic consistency.
 - Mentoring junior authors.
- **Editorial Board Memberships**
 - *Future Neurology* (since 2006)
 - *Neurological Research* (since 2006)
 - *Alzheimer's Disease Research Journal* (since 2007)

PUBLICATIONS:

Frontiers in Bioscience
Guest Managing Editors: [Alireza Minagar](#) and J. Steven Alexander
Special issue: Inflammatory disorders of the nervous system 2003 until 2005

Neurological Research
Guest Editor: **Alireza Minagar**
Special issue: Multiple sclerosis 2006

Neurological Research
Guest Editors: **Alireza Minagar** and Roger E. Kelley
Special issue: Vascular Neurology 2008

Many Publications Inc.
Guest Editor: International Review of Neurobiology-Special issue of Multiple Sclerosis 2007
Alireza Minagar

Elsevier Inc.
Guest Editor: International Review of Neurobiology-Special issue “Dementia” 2009
Alireza Minagar

Elsevier, Inc. 2009
Guest Editors: Journal of Neurological Sciences-Special issue “Gray Matter Pathology in Multiple Sclerosis” 2009

Alireza Minagar/ CV

Robert Zivadinov and Alireza Minagar

Guest Editors: Pathophysiology

Elsevier, Inc.

Pathophysiology -Special issue “Demyelinating Disorders of Central Nervous System” 2010

Alireza Minagar and Robert Zivadinov

Elsevier Inc. 2010

Guest Editor: Neurologic Clinics of North America 2010

Special Topic: “Neurologic Manifestations of Systemic Disease”

Alireza Minagar

Elsevier Inc.

Alireza Minagar, MD, FAAN

Co-Editor in Chief

Neurology and Neurosurgery Yearbook 2011, 2012, 2013

Elsevier, Inc.

Guest Editors: Neurologic Clinics of North America 2012

Special Topic: “Neurologic Emergencies”

Alireza Minagar and Alejandro A. Rabinstein 2012

Elsevier, Inc.

Guest Editors: Neurologic Clinics of North America 2013

Special Topic: “Spinal cord disease”

Alireza Minagar and Alejandro A. Rabinstein

2013

Elsevier Inc.

Guest Editors: Neurologic Clinics of North America 2013

Special Topic: “Cerebellar disease”

Alireza Minagar and Alejandro A. Rabinstein

Elsevier Inc, 2014

Multiple sclerosis: A Mechanistic View

Author: **Alireza Minagar**

Published by: Elsevier 2016

Special Issue: Neurobehavioral Manifestations of Neurological Diseases: Diagnosis & Treatment

Edited by: **Alireza Minagar**, Glen Finney, and Kenneth M. Heilman 2016

Elsevier Inc.

Neuroinflammation

Alireza Minagar

Second Edition

Elsevier Inc. 2018

Multiple Sclerosis: An Overview of Clinical Features, Pathophysiology, Neuroimaging, and Treatment

Editor: **Alireza Minagar, MD**

Published By: Morgan and Claypool Life Sciences

Year of publication: 2014

Published eBooks by Alireza Minagar, MD

On Amazon Kindle

2023-present

Science Communication & Public Education

- Microscopic Marvels: A Layman's Guide to Microbiology's Greatest Discoveries
 - Sugar Legends: Unwrapping the Tales of Iconic Treats
 - Ice Cream: A Global Phenomenon and History
 - The Infinite Code: A Journey Through Computing's Milestones
 - The Ultimate Cosmic Mystery: Are We Alone?
 - Time Unraveled: A Simple Guide to Quantum Travel
 - Gravity Uncovered: The Force That Holds Our Universe Together
 - Exploring the Cosmos: An Astronomical Adventure for the Public
 - Debunking Fake News: A Layman's Guide to Spotting Propaganda
 - Understanding Volcanoes: Geology Studies for the Public Layman
 - Whirlpools Unveiled: The Mysterious Forces of the Deep Blue
 - Plagues and Pandemics: A Historical and Scientific Perspective
 - Veil of Life: Understanding the Ozone Layer's Importance
 - CRISPR-Cas9: The Tool That's Changing Our Genetic Destiny
 - Plastic Planet: Unveiling the Chokehold of Environmental Crisis
 - Thirsty Earth: Exploring the Global Water Crisis
 - Jet Engines and the Aviation Industry: A High-Powered Flight Through Time
 - Cracking the Code: A Layman's Guide to DNA
 - AI Made Easy: A Layman's Guide to Understanding Artificial Intelligence
 - The Mammoth Revival: Exploring the Future of Resurrection
-

History & Culture

- Pompeii and Herculaneum: The Lost Cities Reborn
- The Last Breath of Vesuvius: Unveiling the Legacy of Pompeii and Herculaneum
- Archimedes: The Genius of Syracuse
- Ernest Shackleton: The Antarctic Explorer
- Renaissance Revelations: A Beginner's Guide to Literature and Philosophy
- Rommel Unveiled: Lessons from the Desert Fox's Tactics and Leadership
- Spartacus and the Slave Rebel: The Untold Saga of Gladiators in Ancient Rome
- From Sputnik to SpaceX: Historical Accomplishments in Space Discovery
- The Berlin Wall: A Divided Legacy Explained
- Hannibal: The Conqueror Who Defied Rome

- Amelia Earhart: The Lost Aviatix – Unraveling the Mystery of an American Iconic Pilot
 - Julius Caesar, Marc Antony, and Cleopatra: A Story of Power, Passion, and Betrayal
 - The Borgia Dynasty: Power, Intrigue, and Legacy Unveiled
 - Helen of Troy: The Legendary Woman Who Sparked a War
 - Shadows of Alamut: A Tale of Hassan-i Sabbah and the Assassins
 - Chasing the Cold: Adventures in the Arctic and Antarctic
 - Mankind's Next Frontier: Mars and the Red Planet Revolution
-

Media & Communication

- Cinematic Chronicles: The Story of Film from Silent Beginnings to Technicolor Triumphs
 - The Art of Bullshit: Uncovering the Tricks and Traps of Modern Communication
 - Shadows of Fear: The Villains Who Haunt Hollywood
 - Shadows of the Night: Unraveling the Legacy of Dracula, Nosferatu, and Frankenstein
 - Secrets and Shadows: Cold War Espionage Revealed
-

Philosophy, Society & Psychology

- The Power of No: Reclaiming Boundaries, Inner Freedom, and the Right to Refuse
- Titans of Thought: The 10 Greatest Minds in History
- Preventing Dementia: Mind Matters Through Cognitive Enrichment

Internship, Residency, and Fellowship

1995-1996	Internal Medicine Internship, Mount Vernon Hospital
1996-1997	Neurology Residency, New York University
1997-1999	Neurology Residency, University of Miami
1999-July 2001	Fellowship, Clinical Neuro-immunology/ Multiple Sclerosis Multiple Sclerosis Center of University of Miami, Miami, Florida

Professional Experience

1990-1992	Staff Physician, Iran's Police Force
-----------	--------------------------------------

1990-1993 Head of Emergency Ward, National Iran Oil Company Hospital

Past Teaching Experience

1986-1988 Lecturer, Human Neuroanatomy at Tehran University of Medical Sciences

1999 Preceptor, Neurology Elective, Medical Students

1999-2000 Investigator, Memory Disorders Clinic, University of Miami

Research Responsibilities

1999 Clinical Investigator: Antegren (Natalizumab) Study, Multiple Sclerosis Center, University of Miami

1998 Clinical Investigator: Copaxone Trial in primary progressive multiple sclerosis, Multiple Sclerosis Center, University of Miami

2000-2001
Volume of Clinical Investigator: Effect of Alferon-N (Interferon AN3) on Demyelinating Lesions of Patients with Relapsing Remitting Multiple Sclerosis

2000-2001 Examining neurologist: "VA Persian Gulf Syndrome Study"

2001 Principal Investigator: African American Antiplatelet Stroke Prevention Study: Ticlopidine versus Aspirin (AAASPS)

2001 Principal Investigator for: A double blind, randomized, placebo controlled study of atorvastatin as prevention of cerebrovascular disease in patients with a previous stroke (SPARCL)

2002 Co-Principal Investigator: Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction Study (WARCEF) (NIH UO1 NS 39143 and UO1 NS 43975). Co-PI in LSUHSC-Shreveport, Louisiana Center.

2003 Principal Investigator: The PROOF Study [A Multicenter, Prospective and Retrospective, Long-Term Observational Study of AVONEX and Rebif to Determine the Efficacy, Tolerability, and Safety in Subjects with Relapsing Multiple Sclerosis (MS)]

2003 Principal Investigator: A Double-Blind, Multi-Center, Prospective Study to Evaluate the Percentage Agreement and Utility of Urinary Neural Thread Protein Measurement in Subjects with or without Probable or Possible Alzheimer's Disease

2003 Principal Investigator: Rater blinded, randomized, parallel-group study comparing the Efficacy and Safety of Betaseron® 250ug subcutaneously qod with Avonex® 30ug

- intramuscularly weekly in RRMS patients previously treated with Avonex [ABOVE study].
- 2003 Principal Investigator: Soluble HLA Class I and II in patients with multiple sclerosis. Scientific Medical Grant/Award from Serono-Pfizer
- 2003 Principal Investigator: An open-label trial of safety and efficacy of combination therapy with interferon- β -1a and oral doxycycline in patients with relapsing-remitting multiple sclerosis.
- 2004 Principal Investigator: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Efficacy and Safety of SGS742 in Subjects with Mild to Moderate Alzheimer's Disease. Supported by Saegis Pharmaceutical Inc.
- 2004 Principal Investigator: International, randomized, multicenter, phase IIIb study in patients with relapsing-remitting multiple sclerosis comparing over a treatment period of 104 weeks:
1. Double-blinded safety, tolerability, and efficacy of Betaseron/ Betaferon 250 μ g (8 MIU) and Betaseron/Betaferon 500 μ g (16 MIU), both given subcutaneously every other day, and
2. Rater-blinded safety, tolerability, and efficacy of Betaseron/Betaferon s.c. every other day with Copaxone 20 mg s.c. once daily. BEYOND Study supported by Berlex, Inc.
- 2004 Principal Investigator: A Multi-Center, Randomized, Blinded, Parallel-Group Study of Avonex[®] Compared with Avonex[®] in Combination with Oral Methotrexate, Intravenous Methylprednisolone, or Both in Subjects with Relapsing-Remitting Multiple Sclerosis Who Have Breakthrough Disease on Avonex[®] Monotherapy.[Avonex[®] Combination Trial (ACT), Biogen Idec.
- 2005 DAC-1012: A Phase II Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients with Active, Relapsing Forms of Multiple Sclerosis
- 2006 Principal Investigator: Impact of Neutralizing AntibodieS on Interferon Responsive Genes HighlightTs Biomarker Response
The INSIGHT Study
A Serologic Study to Correlate β -IFN NAb titers to β -IFN Induced Biomarker Response in Patients with Multiple Sclerosis
- 2008-2010 Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis (CONFIRM)

- 2008-2012 Principal Investigator: **BRAVO Study**: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β -1a (Avonex®)
- 2008-present Principal Investigator: **EFC6260**: Phase III Study with Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
- 2008-2009 Principal Investigator: **CARE-MS-1**: A study comparing alemtuzumab to Rebif in patients who are previously untreated for relapsing-remitting multiple sclerosis with at least one relapse in the past 12 months and an MRI proving lesions consistent with MS. Study drug (or placebo) is free of charge of the patient.
- 2008-2009 Principal Investigator: **CARE-MS-2**: A study comparing alemtuzumab to Rebif in patients who are previously untreated for relapsing-remitting multiple sclerosis who have had relapses on other MS medications. Study drug (or Rebif) will be provided to study participants free of charge for the duration of this two year study.
- 2009-2012 Principal Investigator: **BG12**: A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis
- 2009-present Principal Investigator: **BG-12-303**: A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects with Relapsing-Remitting Multiple Sclerosis (109MS303)
- 2009-2012 Principal Investigator: **CAMMS323**: A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif) in Treatment-Naïve Patients with Relapsing-Remitting Multiple Sclerosis
- 2009 Principal Investigator: **CAMMS 324**: An Extension Protocol for Multiple Sclerosis Patients who Participated in Genzyme-Sponsored Studies of Alemtuzumab
- 2009-2011 Principal Investigator: **GENZYME ATAP**: Alglucosidase Alfa Temporary Access Program
- 2009-2012 Principal Investigator: **WARCEF**: Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction
- 2009-2012 Principal Investigator: **ELAN 301**: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of bapineuzumab (AAB-001,

	ELN115727) in Subjects with Mild to Moderate Alzheimer's Disease Who are Apolipoprotein Eε4 Non-Carriers
2009-2012	Principal Investigator: ELAN 302 : A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of bapineuzumab (AAB-001, ELN115727) in Subjects with Mild to Moderate Alzheimer's Disease Who are Apolipoprotein Eε4 Carriers
2009-present	Principal Investigator: IRIS : Insulin Resistance Intervention after Stroke (IRIS) Trial
2010-present	Principal Investigator: Protocol No: MS-GA-301: GALA : A multinational, multicenter, randomized, parallel-group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety, and tolerability of Glatiramer Acetate (GA) injection 40 mg administered three times a week compared to placebo in a double-blind design
2010-present	Principal Investigator: BRAVO EXTENSION : MS-LAQ-302E: A multinational, multicenter, open-label, single-assignment extension of the MS-LAQ-302 (BRAVO) study to evaluate the long-term safety, tolerability, and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing multiple sclerosis.
2010-present	Principal Investigator: PEM : Plasma Endothelial Microparticles in Multiple Sclerosis: A Novel Metric Assay of Disease Activity and Response to Treatment
2010-2011	Principal Investigator: SURPASS : A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects with Relapsing Remitting Multiple Sclerosis (Biogen Idec Protocol Number: 101MS325- SURPASS)
2010-present	Principal Investigator: STRATIFY-2 : JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri®: 101JC402
2011-present	Principal Investigator: ACCLAIM : A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults with Relapsing-remitting Multiple Sclerosis Protocol ITN035AI - ACCLAIM Study
2011-2012	Principal Investigator: EPOC : A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of Fingolimod 0.5 mg/day in

Patients with Relapsing Forms of Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy (EPOC)

Honors and Awards

- 1992 Translation Award for the book “The Century of the Surgeon”, by Iranian Minister of Culture
- 1997 Traveling Fellowship, American Neurological Association
- 1998 Traveling Fellowship for American Epilepsy Society Annual Meeting, Ortho-McNeil
- 1998 Pharmacia-Upjohn Award for Research on the Central Nervous System Disorders
- 1999 Traveling Fellowship, American Neurological Association
- 1999 Chief Resident in Neurology
- 2000 Traveling Fellowship, American Neurological Association
- 2001 Ad hoc Referee and reviewer of articles for **Neurology** and **Annals of Neurology** (7 articles)
- 2002 Ad hoc Referee and reviewer for **Antioxidants and redox signaling** (two articles) and **American Journal of Physiology-Cell physiology** (one article)
- 2003 Ad hoc Referee and reviewer for **Archives of Medical Research** (one article) and **Pathophysiology** (one article), **Southern Medical Journal** (one article)
- 2003 Guest Editor for **Frontiers in Bioscience** Special issue on **inflammatory disorders of the nervous system**
- 2004 Reviewer for **Movement Disorders** (one manuscript)
- 2004 Reviewer for Journal of cellular and Molecular Neurology (one manuscript)
- 2004 Reviewer for Journal of Neuroimmunology (one manuscript)
- 2004 Reviewer for the **American Academy of Neurology [AAN]** (Neurologic manifestations of systemic diseases, Florida 2005)
- 2005 Co-chair of AAN Session on “Internal Medicine and Neurology, Miami, Florida 2005
- 2005 Grant Reviewer for American Heart Association: Ohio Valley Section

2006	Guest Editor of Neurological Research Special issue “Multiple Sclerosis”
2006	Reviewer for Journal of Neuropediatrics, Journal of Antiviral Research, Journal of Neuroimaging, European Journal of Neurology
2007-present	Scientific Topic Chair of American Academy of Neurology Neurologic Manifestations of Systemic Disease
2008	Guest Editor of Neurological Research Special issue “Vascular Neurology”
2009	Guest Editor of a special issue of Journal of Neurological Sciences Special issue “Gray Matter Pathology in Multiple Sclerosis”

Society Memberships

1996	American Academy of Neurology
1996	American College of Physicians
2002	Society for Neuroscience
2002	The Microcirculatory Society
2001	American Academy for Advancement of Science
2003	International Society of Neuro-immunology
2004	Association of Clinical Research Professionals (ACRP)
2007	American Neurological Association
2009	Fellow of American Academy of Neurology (FAAN)
2011	Stanford’s Who’s Who Elected as of 2011
2013	Fellow of American Neurological Association (FANA)
2013	International Society of Neurovascular Diseases

Invited Lectureships

1999	Pramipexole and Treatment of PSP, Neurology Grand Round, Department of Neurology, University of Miami
1999	Multiple Sclerosis and Brian Tumors, Consortium of Multiple Sclerosis Centers
1999	Devic’s Disease: A Therapeutic Challenge, Consortium of Multiple Sclerosis Centers

Alireza Minagar/ CV

- 1999 Multiple Sclerosis: Neurobehavioral Aspects, National MS Society
- 2001 Platform presentation of Cytokine Profile in NeuroAIDS
American Academy of Neurology, Philadelphia May 2001
- 2002 Multiple Sclerosis: Future Directions
Neuro-Update at Louisiana State University Health Sciences Center at Shreveport, Louisiana
- 2003 Multiple sclerosis, blood brain barrier, and interferons: Mechanisms
Visiting Professor: Grand Round Department of Neurology
University of Oklahoma
- 2004 Cerebral endothelial cells, multiple sclerosis, and interferons
Visiting Professor: Grand Round Department of Neurology
University of Texas, San Antonio, TX
- 2005 MS and endothelium
Visiting Professor: Grand Round Department of Neurology
Creighton University, Omaha, Nebraska
- 2005 Therapies for MS
Grand Round Department of Anesthesiology
LSUHSC-Shreveport, LA
- 2006 Visiting Professor
Grand Rounds at Dept. Immunology
Tehran University of Medical Sciences and Iranian MS Society
Tehran, IRAN
- 2008 Visiting Professor
Grand Rounds at Depts. Immunology and Neurology
Tehran University of Medical Sciences and Iranian MS Society
Tehran, IRAN
- 2008 Visiting Professor
Grand Rounds at Dept. Neurology
Isfahan University of Medical Sciences
Isfahan, IRAN
- 2009 Visiting Professor
Grand Rounds at Dept. Neurology
State University of New York (SUNY) at Buffalo, NY
Buffalo Neuroimaging Analysis Center
New York, USA
Subject: MS and Cerebral endothelium
- 2010 American Academy of Neurology
Annual meeting in Toronto Canada
Platform presentation
The effects of high dose interferon- β 1a on plasma microparticles: Correlation with MRI parameters.

This presentation was selected as one of the best presentations and was re-presented for Scientific highlights of the AAN 2010

- 2011 Visiting Neurology Professor
Isfahan University of Medical Sciences and
MS Center of IRAN
- 2012 Visiting Neurology Professor
SUNY Buffalo, Buffalo, NY
Multiple sclerosis and endothelial frontier
- 2012 International guest speaker of International MS Congress
IRAN, Tehran
- 2023 Role of Artificial Intelligence in Diagnosis and Treatment of
Multiple Sclerosis
International guest speaker of International MS Congress
IRAN, Tehran
- 2024 Role of Artificial Intelligence and Machine Learning in
Diagnosis and Treatment of Multiple Sclerosis
International guest speaker of International MS Congress
IRAN, Tehran

Bibliography

Scientific Articles in Peer-Reviewed Journals

1. Parker RS, Abdel-Dayem H, Silverman S, Hutchinson M, **Minagar A**. A protocol for multi-disciplinary assessment of the outcome of traumatic brain injury in adults after two years. J Rehabil Outcomes Measurements 1997;1:1-22.
2. DeToledo JC, **Minagar A**, Lowe MR, Ramsay RE. Skin eruptions with gabapentin in a patient with AED-induced Steven-Johnson's syndrome. Therapeutic Drug Monitoring 1999;1:137-138.
3. Shulman LM, **Minagar A**, Weiner WJ. Pramipexole in progressive supranuclear palsy. Neurology 1999;52:873-874.
4. **Minagar A**, David NJ. Bilateral infarction in the territory of anterior cerebral arteries. Neurology 1999;10:886-888.
5. Shulman LM, **Minagar A**, Weiner WJ. Prediagnosed, esophageal obstruction, and Parkinson's disease. Neurology 1999;52:670-671.
6. Shulman LM, **Minagar A**, Sharma K, Weiner WJ. Amantadine induced neuropathy. Neurology 1999;53:1862-1865.
7. Weiner WJ, **Minagar A**, Shulman LM. Transdermal induced psychosis in a patient with Parkinson's disease. Neurology 1999;53:433-434.

8. Shulman LM, Minagar A, Weiner WJ. The effect of pregnancy in Parkinson's disease. *Movement Disorders* 2000;15:132-135.
9. Minagar A, Sheremata WA, Hume A, Koller M, Vollmer T. Reduction of relapses in multiple sclerosis after Natalizumab (Antegren) treatment. *International MS Journal* (On line) March 15, 2000
10. Minagar A, Sheremata WA. Glossopharyngeal neuralgia and MS. *Neurology* 2000; 54:1368-1370.
11. Weiner WJ, Minagar A, Shulman LM. Quetiapine for levodopa-induced psychosis in PD. *Neurology* 2000;54:1538.
12. Shulman LM, Minagar A, Rabinstein A, Weiner WJ. The use of dopamine agonists in very elderly patients with Parkinson's disease. *Movement Disorders* 2000;15:664-668.
13. Minagar A, Sevush A, Bertram A. Cerebral ventricles are smaller in Hispanic than non-Hispanic patients with Alzheimer's disease. *Neurology* 2000;55:446-448.
14. DeToledo JC, Minagar A, Lowe MR. Persisting aphasia as the sole manifestation of partial status epilepticus. *Clin Neurol Neurosurg.* 2000;102(3):144-148.
15. Minagar A, Schatz NJ, Glaser JS. One-and-a-half-syndrome and tuberculosis of the pons in a patient with AIDS. *AIDS Patient Care and STDs.* 2000;14:461-464.
16. Gass C, Whitney J, Minagar A, Kuljis R. Crossed aphasia and cerebral localization of functional a case study. *Arch Clin Neuropsychol.* 2000 Nov;15(8):722.
17. Minagar A, Schatz NJ, Glaser JS. Liposuction and ischemic optic neuropathy: Case report and review of literature. *Journal of Neurological Sciences.* 2000; 181:132-136.
18. Minagar A, Sheremata WA. Glossopharyngeal neuralgia and MS. *Current Awareness in Biomedicine: Autoimmune Diseases.* 2000
19. Minagar A, Sheremata WA. Treatment of Devic's Disease with methotrexate and prednisone. *Int J MS Care* [Serial on-line]. Dec 2000;2(4).
20. Minagar A, Lowis GW. Dr Heinrich Irenaeus Quincke (1842ndash;1922): clinical neurologist of Kiel. *J Med Biogr.* 2001;9(1):12-15.
21. Romaguera RL, Minagar A, Bruce JH, Jagid JR, Falcone S, Curless RG, Ragheb J, Morrison G. Adrenocortical carcinoma with cerebral metastasis in a child: A case report and review of literature. *Clinical Neurology and Neurosurgery* 2001;103:46-50.
22. Minagar A, Jy W, Jimenez JJ, Sheremata WA, Mauro LM, Mao WW, Horstman LL, and Ahn YS. Elevated plasma endothelial microparticles in multiple sclerosis. *Neurology* 2001;56: 1319-1323.
23. Lieberman A, Minagar A, Pinter MM. The Efficacy of Pramipexole in the Treatment of Parkinson's Disease. *Rev Contemp Pharmacother* 2001;12:59-86.

24. **Minagar A.**, Shapshak P, Heyes M, Sheremata WA, Fujimara R, Ownby R, Goodkin K, Eisdorfer K. Microglia and astrocytes in neuro-AIDS, alzheimers disease, and multiple sclerosis. ScientificWorldJournal. 2001 Jan 1;1(1 Suppl 3):69.
25. **Minagar A.**, DeToledo JC, Falcone S. Cortical-subcortical lesions in “reversible posterior leukoencephalopathy syndrome”. Encephalopathy or seizures? Journal of Neurology. 2001;248:537-540.
26. **Minagar A.**, Weiner WJ. Adolf Kussmaul and his respiratory sign. J Med Biogr 2001;9(3): 181-183.
27. **Minagar A.**, Sheremata WA, Tusa RJ. Perverted head-shaking nystagmus: A possible mechanism. Neurology 2001;57:887-889.
28. Lowis GW, Sheremata WA, **Minagar A.** Epidemiologic features of HTLV-II. Serologic and molecular evidence. Annals of Epidemiology 2002;12(1): 46-66.
29. Shulman LM, Wen X, Weiner WJ, Bateman D, RN , **Minagar A.** Duncan R, Konefal J. Acupuncture therapy for the symptoms of Parkinson's disease. Movement Disorders 2002;4(17):799-802.
30. **Minagar A.**, Sheremata WA, Weiner WJ. Transient Movement Disorders in Multiple Sclerosis. Parkinsonism and related disorders 2002;9(2):111-113.
31. Sasaki M, Jordan P, Joh T, Itoh M, Jenkins M, Pavlick K, **Minagar A.** Alexander JS. Melatonin reduces TNF- α induced expression of MAdCAM-1 via inhibition of NF- κ B. BMC Gastroenterol. 2002 Apr 24;2(1):9.
32. **Minagar A.**, Rabinstein A, Shulman LM, Weiner WJ. Movement Disorders during Pregnancy. Adv Neurol 2002;90:213-226.
33. Lowis GW, **Minagar A.** Alexander Gordon of Aberdeen and the discovery of the contagiousness of puerperal fever. J Med Biogr. 2002;10(3):150-154.
34. **Minagar A.** Hardjasudarma M, Kelley RE. Neurosarcoidosis. Neurology. 2002 Aug 13;59(3):477.
35. **Minagar A.** Alexander JS, Long AC, Fowler MR, and Kelley RE. Devic Disease: Clinical Course, Pathophysiology, and Management. Pathophysiology. 2002;9(1):33-40.
36. **Minagar A.** Shapshak P, Fujimura R, Ownby R, Heyes M and Eisdorfer C. The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J Neurological Sciences 2002;202:13-23.
37. DeToledo JC, **Minagar A.** Lowe MR. Lidocaine-induced Seizures in Patients with History of Epilepsy: Effect of Antiepileptic Drugs. Anesthesiology 2002 Sep;97(3):737-739.
38. Sasaki M, Ostanin D, Elrod JW, Oshima T, Jordan P, Itoh M, Joh T, **Minagar A.** and Alexander JS. TNF- α Induced Endothelial Cell Adhesion Molecule Expression Is Cytochrome P450 Monooxygenase Dependent. Am J Physiol Cell Physiol. 2003 Feb;284(2):C422-8.

39. Kelley RE, Minagar A, Kelley BJ, and Brunson R. Trans-cranial Doppler Monitoring of Response to Therapy for Meningovascular Syphilis. *Journal of Neuroimaging* 2003;13:85-87.
40. Miller DH, Khan OA, Sheremata WA, et al. for A controlled trial of natalizumab for relapsing multiple sclerosis. *N Engl J Med.* 2003;348(1):15-23.
41. Shulman LM, Minagar A, and Weiner WJ. Reversal of parkinsonism following liver transplantation *Neurology* 2003; 60: 519.
42. Ruland S, Raman R, Chaturvedi S, Leurgans S, Gorelick PB, et al. for Awareness, treatment, and control of vascular risk factors in African Americans with stroke. *Neurology.* 2003;60:64-68.
43. Rashidi M, DaSilva VR, Minagar A, Rutka JT. Nonmalignant pediatric brain tumors. *Curr Neurol Neurosci Rep.* 2003;3:200-205.
44. Kelley RE, Minagar A. Cardioembolic Stroke: An Update. *Southern Medical Journal* 2003;96:343-349.
45. Minagar A, Ostanin D, Long AC, Jennings M, Kelley RE, MD, Sasaki M, Alexander JS. Serum from multiple sclerosis patients down-regulates occludin and VE-cadherin expression in cultured endothelial cells. *Multiple Sclerosis* 2003;9:235-238.
46. Minagar A, Ragheb J, Kelley RE. The Edwin Smith surgical papyrus: description and analysis of the earliest case of aphasia. *J Med Biogr.* 2003;11:114-117.
47. Gorelick PB, Richardson D, Kelly M, Ruland S, Hung E, Harris Y, Kittner S, Leurgans S, et al for: Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. *JAMA.* 2003;289(22):2947-2957.
48. Elrod J W, Park J H, Oshima T, Sharp C D, Minagar A, Alexander J S. Expression of junctional proteins in human platelets. *Platelets* 2003; 14:247 –251.
49. Gonzalez Toledo EC, Gomez EB, Minagar A, Hardjasudarma M, Hebert J. Encefalopatía Posterior reversible Diagnostico VOLUMEN XII- NUMERO 123 – 2003.
50. Adamashvili I, Wolf R, Aultman D, Milford EL, Jaffe S, Hall V, Pressly T, Minagar A, Kelley R. Soluble HLA-I (s-HLA-I) synthesis in systemic lupus erythematosus. *Rheumatol Int.* 2003 Jul 23.
51. Sharp CD, Hines I, Houghton J, Warren A, Jackson IV TH, Jawahar A, Nanda A, Elrod JW, Long A, Minagar A, Alexander JS. Glutamate Causes a Loss in Human Cerebral Endothelial Barrier Integrity through the Activation of the N-Methyl-D-Aspartate Receptor (NMDAR). *Am J Physiol Heart Circ Physiol.* 2003 Jul 31.
52. Minagar A. Gray matter involvement in multiple sclerosis: A new window into pathogenesis. **Editorial.** *Journal of Neuroimaging* 2003;4:291-292.
53. Lowis GW and Minagar A. The Neglected Research of Egas Moniz of Internal Carotid Artery (ICA) Occlusion. *Journal of the History of the Neurosciences*2003;12:286-291.

54. **Minagar A**, Alexander JS. Blood-brain barrier disruption in multiple sclerosis. *Multiple Sclerosis* 2003; 9: 540-549.
55. Mousavizadeh K, Dehpour AR, **Minagar A**, Ghafourifar P. Uric acid: a novel treatment strategy for multiple sclerosis. *Trends Pharmacol Sci.* 2003 ;24(11):563-564.
56. Jaffe SL, Glabus MF, Kelley RE, **Minagar A**. Acute verbal dyspraxia, a rare presentation in multiple sclerosis: a case report with MRI localization *Multiple Sclerosis* 2003;9:630-632.
57. Sharp CD, Fowler M, Jackson TH, Houghton J, Warren AC, Nanda A, Chandler I, Cappell B, Long A, **Minagar A**, Elrod JW, Alexander JS. Human neuroepithelial cells express NMDA receptors *BMC Neuroscience* 2003, 4:28 (13 November 2003).
58. **Minagar A**, Long A, Ma T, Jackson TH, Kelley RE, Ostanin DV, Sasaki M, Warren AC, Jawahar A, Cappell B, Alexander JS. Interferon (IFN)-beta1a and IFN-beta1b Block IFN-gamma-Induced Disintegration of Endothelial Junction Integrity and Barrier. *Endothelium.* 2003; 10(6): 299-307.
59. The SPARCL Investigators. Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study. *Cerebrovascular Diseases.* 2003;16:389-395.
60. Jawahar A, Jawahar LL, Nanda A, Sharp CD, Warren A, Elrod JW, Jennings M, Alexander JS and **Minagar A**. Stereotactic radiosurgery using the Leksell Gamma knife: current trends and future directives. *Frontiers in Bioscience* 2004;9; 932-938.
61. Shapshak P, Duncan R, **Minagar A**, Rodriguez de la Vega P, Stewart RV, Goodkin K. Elevated expression OF IFN-gamma in the HIV-1 infected brain. *Frontiers in Bioscience* 2004; 9, 1073-1081.
62. Kelley RE, Dellabadia J, **Minagar A**, Kelley BJ, Brunson R. Neuroimaging of the complications of epilepsy surgery. *Journal of Neuroimaging* 2004;14(1):33-41.
63. DellaBadia J, Jaffe SL, Singh J, **Minagar A**. An occipital lobe epileptogenic focus in a patient with West Nile encephalitis. *European Journal of Neurology* 2004;11:111-113.
64. Green R, Scott LK, **Minagar A**, Conrad S. Sepsis associated encephalopathy (SAE): a review. *Frontiers in Bioscience* 2004; 9:1637-1641.
65. Sasaki M, Elrod JW, Jordan P, Itoh M, Joh T, **Minagar A**, Alexander JS. CYP450 dietary inhibitors attenuate TNF- α -stimulated endothelial molecule expression and leukocyte adhesion. *AM J Physiology Cell Physiology* 2004;286:C931-C939.
66. Kablinger AS, Czerwinski WP, **Minagar A**. Divalproex Versus Valproate in Patients With Bipolar Disorder. *Journal of Clinical Psychopharmacology.* 2004;24(2):231-232.
67. **Minagar A**. GALOP Syndrome: A Treatable Immune-mediated Late-age Onset Polyneuropathy with Gait Ataxia. Editorial. *South Med J.* 2004;97(4):333-334.
68. Kelley RE, **Minagar A**. Memory complaints and dementia. *Prim Care.* 2004;31(1):129-148.

69. **Minagar A**, Kelley RE. Movement disorders. Prim Care. 2004;31(1):111-127.
70. Scott KL, Vachharajani V, Mynatt RL, **Minagar A**, Conrad SA. Brain RNA expression in obese vs lean mice after LPS-induced systemic inflammation. Frontiers in Bioscience. 2004;9:2686-2696.
71. Jawahar A, Matthew RE, **Minagar A**, Shukla D, Zhang JH, Willis BK, Ampil F, Nanda A. Gamma knife surgery in the management of brain metastases from lung carcinoma: a retrospective analysis of survival, local tumor control, and freedom from new brain metastasis. J Neurosurg. 2004;100(5):842-847.
72. Shapshak, P , Duncan, R, Torres-Munoz JE, Duran EM, **Minagar A**, and Petito CK. Analytic approaches to differential gene expression in AIDS versus control brains. Frontiers in Bioscience. 2004;9:2935-2946.
73. Jy W, **Minagar A**, Jimenez JJ, Sheremata WA, Mauro LM, Horstman LL, Bidot C, Ahn YS. Endothelial microparticles (EMP) bind and activate monocytes: elevated EMP-monocyte conjugates in multiple sclerosis. Frontiers in Bioscience 2004;9:3137-3144.
74. **Minagar A**, Gonzalez Toledo E, Alexander JS, and Kelley RE. Pathogenesis of brain and spinal cord atrophy in Multiple Sclerosis: Mechanisms. Journal of Neuroimaging. 2004;14:5S-10S.
75. **Minagar A**, Shapshak P, Duran EM, Kablinger AS, Alexander JS, Kelley RE, Ramman S, Kazic T. HIV-Associated Dementia, Alzheimer's disease, Multiple Sclerosis, and Schizophrenia: Gene expression review. J Neurol Sciences. 2004;224(1-2):3-17.
76. Sharp CD, Houghton J, Elrod JW, Warren A, Jackson TH 4th, Jawahar A, Nanda A, **Minagar A**, Alexander JS. N-methyl-D-aspartate receptor activation in human cerebral endothelium promotes intracellular oxidant stress. Am J Physiol Heart Circ Physiol. 2005 Apr;288(4):H1893-9. Epub 2004 Dec 2.
77. Sasaki M, Jordan P, Welbourne T, **Minagar A**, Joh T, Ando T, Elrod J, Alexander JS. Troglitazone, a PPAR-gamma activator prevents endothelial cell adhesion molecule expression and lymphocyte adhesion mediated by TNF-alpha. BMC Physiol. 2005;5(1):3.
78. Ando T, Jordan P, Wang Y, Itoh M, Joh T, Sasaki M, Elrod JW, Carpenter A, Jennings MH, **Minagar A**, Alexander JS. MAdCAM-1 expression and regulation in murine colonic endothelial cells In Vitro. Inflamm Bowel Dis 2005;11:258-264.
79. Scott LK, Vachharajani V, **Minagar A**, Mynatt RL, Conrad SA. Differential RNA expression of hepatic tissue in lean and obese mice after LPS-induced systemic inflammation. Front Biosci. 2005;10:1828-1834.
80. Bakshi R, **Minagar A**, Jaisani Z, Wolinsky JS. II. Neuroimaging in the Therapy of Neurological Disorders: Imaging of Multiple Sclerosis: Role in Neurotherapeutics. NeuroRx 2005;2:277-303.
81. Schwendimann RN, Burton E, **Minagar A**. Management of myasthenia gravis. Am J Ther. 2005;12(3):262-268.
82. Alekseeva N, Kablinger AS, Pinkston JB, Gonzalez-Toledo EC, **Minagar A**. Hereditary ataxia and behavior. Advances in Neurology. 2005;96:275-284.

83. Jimenez JJ, Jy W, Mauro LM, Horstman LL, Ahn ER, Ahn YS, **Minagar A**. Elevated endothelial microparticle–monocyte complexes induced by multiple sclerosis plasma and the inhibitory effects of interferon- β 1b on release of endothelial microparticles, formation and transendothelial migration of monocyte–endothelial microparticle complexes. *Multiple Sclerosis*; 2005;11 (3): 310-315.
84. Duran EM, Shapshak P, Worley J, **Minagar A**, Ziegler F, Haliko S, Moleon-Borodowsky I, Haslet PAJ. Presenilin-1 detection in brain neurons and FOXP3 in peripheral blood mononuclear cells: normalizer gene selection for real time reverse transcriptase pcr using the $\Delta\Delta$ Ct method. *Frontiers in Bioscience* 2005; 10, 2955-2965.
85. Adamashvili I, **Minagar A**, Gonzalez-Toledo E, Featherston L, Kelley RE. Soluble HLA measurement in saliva and cerebrospinal fluid in Caucasian patients with multiple sclerosis: a preliminary study. *Journal of Neuroinflammation* 2005, 2:13.
86. Heldmann M, Behm W, Reddy MP, Bozeman C, Welman G, Abreo F, **Minagar A**. Pseudotumoral Renal Sarcoid: MRI, PET, and MDCT Appearance with Pathologic Correlation. *AJR Am J Roentgenol*. 2005 Sep;185(3):697-699.
87. **Minagar A**, Adamashvili I, Jaffe SL., Glabus MF, Gonzalez-Toledo E, Kelley RE. Soluble HLA Class I and Class II Molecules in Relapsing-Remitting Multiple Sclerosis: Acute Response to Interferon- β 1a Treatment and Their Use as Markers of Disease Activity. *Ann NY Acad Sci* 2005 1051: 111-120.
88. Jaffe SL, **Minagar A**. Demyelinating pseudotumor. *Arch Neurol*. 2005;62(9):1466-1467.
89. Sheremata WA, **Minagar A**, Alexander JS, Vollmer T. The role of alpha-4 integrin in the aetiology of multiple sclerosis: current knowledge and therapeutic implications. *CNS Drugs*. 2005;19(11):909-922.
90. **Minagar A**, Gonzalez-Toledo E, Pinkston J, Jaffe SL. Neuroimaging in Multiple Sclerosis. *Int Rev Neurobiol*. 2005;67PB:165-201.
91. Shapshak P, Duncan R, Nath A, Turchan J, Pandjassarame K, Rodriguez H, Duran EM, Ziegler F, Amaro E, Lewis A, Rodriguez A, **Minagar A**, Davis W, Seth R, Elkomy FF, Chiappelli F, Kazic T. Gene Chromosomal Organization and Expression in Cultured Human Neurons Exposed to Cocaine and HIV-1 proteins gp120 and tat: Drug Abuse and NeuroAIDS. *Front Biosci*. 2006 May 1;11:1774-1793.
92. Shapshak P, Duncan R, Turchan J, Nath A, **Minagar A**, Kanguane P, Davis W, Chiappelli F, Elkomy F, Seth R, Kazic T. Biotransformatics models in drug abuse and Neuro-AIDS: Using and developing databases. *Bioinformatics* 2006; 1(3):86-88.
93. Patwardhan RV, **Minagar A**, Kelley RE, Nanda A. Neurosurgical treatment of multiple sclerosis. *Neurol Res*. 2006;28(3):320-325.
94. Gonzalez-Toledo E, Kelley RE, **Minagar A**. Role of magnetic resonance spectroscopy in diagnosis and management of multiple sclerosis. *Neurol Res*. 2006;28(3):280-283.
95. **Minagar A**, Jy W, Jimenez JJ, Alexander JS. Multiple sclerosis as a vascular disease. *Neurol Res*. 2006;28(3):230-235.

96. **Minagar A.** Multiple sclerosis: current knowledge and future directions. *Neurol Res.* 2006;28(3):227-229.
97. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Silleesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (**SPARCL**) **Investigators.** High-dose atorvastatin after stroke or transient ischemic attack. *N Engl J Med.* 2006;355(6):549-559.
98. Sheremata WA, Jy W, Delgado S, **Minagar A.** McLarty J, Ahn Y. Interferon-beta-1a reduces plasma CD31+ endothelial microparticles (CD31+EMP) in multiple sclerosis. *J Neuroinflammation.* 2006 Sep 4;3(1):23.
99. **Minagar A.** Early onset multiple sclerosis: more emphasis on early treatment. *Neuropediatrics.* 2006;37:207-278.
100. Goodman I, Golden G, Flitman S, Xie K, McConville M, Levy S, Zimmerman E, Lebedeva Z, Richter R, **Minagar A.** Averbach P. A multi-center blinded prospective study of urine neural thread protein measurements in patients with suspected Alzheimer's disease. *J Am Med Dir Assoc.* 2007 Jan;8(1):21-30. Epub 2006 Sep 29.
101. Korniychuk E, Dempster JM, O'connor E, Alexander JS, Kelley RE, Kenner M, Menon U, Misra V, Hoque R, Gonzalez-Toledo E, Schwendimann RN, Smith S, **Minagar A.** Evolving Therapies For Multiple Sclerosis. *Int Rev Neurobiol.* 2007;79C:571-588.
102. Zivadinov R, Uxa L, Bratina A, Bosco A, Srinivasaraghavan B, **Minagar A.** Ukmar M, Benedetto SY, Zorzon M. HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 Alleles are Associated With More Severe Disease Outcome on Mri in Patients With Multiple Sclerosis. *Int Rev Neurobiol.* 2007;79C:521-535.
103. Hoque R, Ledbetter C, Gonzalez-Toledo E, Misra V, Menon U, Kenner M, Rabinstein AA, Kelley RE, Zivadinov R, **Minagar A.** The Role of Quantitative Neuroimaging Indices in the Differentiation of Ischemia From Demyelination: An Analytical Study With Case Presentation. *Int Rev Neurobiol.* 2007;79C:491-519.
104. Dolezal O, Dwyer MG, Horakova D, Havrdova E, **Minagar A.** Balachandran S, Bergsland N, Seidl Z, Vaneckova M, Fritz D, Krasensky J, Zivadinov R. Detection of Cortical Lesions is Dependent on Choice of Slice Thickness in Patients with Multiple Sclerosis. *Int Rev Neurobiol.* 2007;79C:475-489.
105. Horstman LL, Jy W, **Minagar A.** Bidot CJ, Jimenez JJ, Alexander JS, Ahn YS. Cell-Derived Microparticles and Exosomes in Neuroinflammatory Disorders. *Int Rev Neurobiol.* 2007;79C:227-268.
106. **Minagar A.** Carpenter A, Alexander JS. The Destructive Alliance: Interactions of Leukocytes, Cerebral Endothelial Cells, and the Immune Cascade in Pathogenesis of Multiple Sclerosis. *Int Rev Neurobiol.* 2007;79C:1-11.
107. **Minagar A.** Adamashvili I, Kelley RE, Gonzalez-Toledo E, McLarty J, Smith SJ. Saliva soluble HLA as a potential marker of response to interferon-beta1a in multiple sclerosis: A preliminary study. *J Neuroinflammation.* 2007 Jul 1;4(1):16.
108. Alexander J.S, **Minagar A.** Harper M, Robinson-Jackson Sherry, Jennings Merylyn, Smith SJ. Proteomic Analysis of Human Cerebral Endothelial Cells Activated by Multiple

- Sclerosis Serum and IFN β -1b. *J Mole Neurosci* 2007;32(3):169-178.
109. Ando T, Langley RR, Wang Y, Jordan PA, **Minagar A**, Alexander JS, Jennings MH. Inflammatory cytokines induce MAdCAM-1 in murine hepatic endothelial cells and mediate alpha-4 beta-7 integrin dependent lymphocyte endothelial adhesion In Vitro. *BMC Physiology* 2007; 7:10.
 110. Bidot CJ, Horstman LL, Jy W, Jimenez JJ, Bidot Jr C, Ahn YS, Alexander JS, Gonzalez-Toledo E, Kelley RE, **Minagar A**. Clinical and neuroimaging correlates of antiphospholipid antibodies in Multiple Sclerosis: A preliminary study. *BMC Neurol.* 2007;7(1):36.
 111. **Minagar A**, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis. *Arch Neurol.* 2008;65(2):199-204.
 112. Alexander JS, Ando A, Jordan P, Wang Y, **Minagar A**, Jennings MH, Joh T TNF- α Regulated MAdCAM-1 Expression in Pancreatic Microvessel Endothelium: A Possible Role for MAdCAM-1 in Pancreatitis? *The Open Journal of Gastroenterology* 2008;2:1-8.
 113. **Minagar**, Commins D, Alexander JS, Hoque R, Chiappelli F, Singer EJ, Nikbin B, Shapshak P. NeuroAIDS: Characteristics and Diagnosis of the Neurological Complications of AIDS. *Mol Diagn Ther.* 2008;12(1):25-43.
 114. Hoque R, Gonzalez-Toledo E, **Minagar A**, Kelley RE. Circuitous embolic hemorrhagic stroke: carotid pseudoaneurysm to fetal posterior cerebral artery conduit: a case report. *J Med Case Reports.* 2008;2(1):61.
 115. **Minagar A**, Murray TJ, Investigators FT. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF. *Curr Med Res Opin.* 2008 Feb 29; [Epub ahead of print].
 116. Evidence of platelet activation in multiple sclerosis. Sheremata WA, Jy W, Horstman LL, Ahn YS, Alexander JS, **Minagar A**. *Journal of Neuroinflammation* 2008, 5:27.
 117. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Zivadinov R, Teder AT, Filippi M, **Minagar A**, Stuve O, Lassmann H, Racke MK, Dwyer MG, Frohman EM, Khan O. *Neurology* 2008 71: 136-144.
 118. Alzheimer's disease and HIV associated dementia related genes: I. location and function Shapshak P, Rodriguez HE, Kayathri R, Levine A, Chiappelli F, **Minagar A**. *Bioinformatics* 2008; 2(8): 348-357.
 119. Sin AH, Gonzalez-Toledo E, Fowler M, **Minagar A**, Nanda A. Amyloidoma presenting as a butterfly glioma on positron emission tomography scan and magnetic resonance-spectroscopy: a case report and review of the literature. *J La State Med Soc.* 2008;160(1):44-7, 49-50.
 120. Shapshak P, Rodriguez HE, Kayathri R, Levine A, Chiappelli F, **Minagar A**. Alzheimer's disease and HIV associated dementia related genes: I. location and function. *Bioinformatics.* 2008 May 29;2(8):348-57.
 121. Goldstein LB, Amarenco P, Lamonte M, Gilbert S, Messig M, Callahan A, Hennerici M, Sillesen H, Welch KM; SPARCL Investigators.

- Bogousslavsky J., **Minagar A**, De Bastos M. **Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Stroke. 2008;39(9):2444-2448.**
122. Dwyer, MG, Bergsland N, Saluste Erik, Sharma Jitendra, Jaisani Z, Durfee J, Abdelrahman N, **Minagar A**, Hoque R; Munschauer FE, Zivadinov R. Application of hidden Markov random field approach for quantification of perfusion/diffusion mismatch in acute ischemic stroke. *Neurological Research* 2008;30:827-834.
124. **Minagar A**, Kelley RE. Vascular neurology: a winding but illuminating road of progress. *Neurological Research* 2008;30:773-774.
125. Zivadinov R, Bergsland M, Stosic M, Sharma J, Nussenbaum F, Durfee J, Hani N, Abdelrahman N, Jaisani Z, **Minagar A**, Hoque R, Munschauer FE, Dwyer MG. Use of perfusion- and diffusion-weighted imaging in differential diagnosis of acute and chronic ischemic stroke and multiple sclerosis. 2008; *Neurological Research* 30:816-826.
126. Misra V, Hoque R, Gonzalez-Toledo Eduardo, Kelley RE, **Minagar A**. Pseudo-subarachnoid hemorrhage in a patient with acute cerebellar infarction. *Neurological Research*. 2008;30:813-815.
127. **Minagar A**, Alexander JS, Kelley RE, Harper M, Jennings MH. Proteomic Analysis of Human Cerebral Endothelial Cells Activated by Glutamate/MK-801: Significance in Ischemic Stroke Injury. *J Mol Neurosci*. 2008 Oct 9.
128. Shapshak P, Rodriguez HE, Kayathri R, Levine A, Francesco Chiappelli, **Minagar A**. ALZHEIMER'S DISEASE AND HIV ASSOCIATED DEMENTIA RELATED GENES. I. LOCATION AND FUNCTION, *Bioinformation*, *in press*, 2008.
129. Patterson JC 2nd, Lilien DL, Takalkar A, Kelley RE, **Minagar A**. Potential Value of Quantitative Analysis of Cerebral PET in Early Cognitive Decline. *Am J Alzheimers Dis Other Demen*. 2008 Nov 10.
130. Shapshak P, Chiappelli F, Commins D, Singer E, Levine AJ, Somboonwit C, **Minagar A**, Pellionisz AJ. Molecular epigenetics, chromatin, and NeuroAIDS/HIV: Translational implications. *Bioinformation*. 2008;3(1):53-57. Epub 2008 Oct 7.
131. Chiappelli F, Shapshak P, Commins D, Singer E, **Minagar A**, Oluwadara O, Prolo P, Pellionisz AJ. Molecular epigenetics, chromatin, and NeuroAIDS/HIV: Immunopathological implications. *Bioinformation*. 2008;3(1):47-52. Epub 2008 Oct 7.
132. Schwendimann RN, Harris MK, Elliott DG, Menon U, Gonzalez-Toledo E, Zivadinov R, Pressly TA, Kelley RE, Hoque R, Fowler M, Maghzi AH, Etemadifar M, Saadatnia M, **Minagar A**. Neurosarcoidosis: Clinical Features, Diagnosis, and Management. *Am J Ther*. 2008 Dec 15.
133. Harris MK, Hadi Maghzi A, Etemadifar M, Kelley RE, Gonzalez-Toledo E, **Minagar A**. Acute demyelinating disorders of the central nervous system. *Curr Treat Options Neurol*. 2009;11(1):55-63.
134. Horstman LL, Jy W, Bidot CJ, Ahn YS, Kelley RE, Zivadinov R, Maghzi AH, Etemadifar M, Mousavi SA, **Minagar A**. Antiphospholipid antibodies: Paradigm in

- transition. J Neuroinflammation. 2009 Jan 20;6(1):3.
135. Ramasamy DP, Benedict R, Cox JL, Fritz D, Abdelrahman N, Hussein S, **Minagar A**, Dwyer MG, Zivadinov R. Extent of cerebellum, subcortical and cortical atrophy in patients with MS A case-control study. J Neurol Sci. 2009 Feb 5.
135. Borazanci AP, Harris MK, Schwendimann RN, Gonzalez-Toledo E, Maghzi AH, Etemadifar M, Alekseeva N, Pinkston J, Kelley RE, **Minagar A**. Multiple Sclerosis: Clinical features, pathophysiology, neuroimaging and future therapies. Future Neurology 2008.
136. Amarenco P, Benavente O, Goldstein LB, Callahan A 3rd, Sillesen H, Hennerici MG, Gilbert S, Rudolph AE, Simunovic L, Zivin JA, Welch KM; **on behalf of the SPARCL Investigators (Minagar A)**. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes. Stroke. 2009 Feb 19. [Epub ahead of print]
137. Chaturvedi S, Zivin J, Breazna A, Amarenco P, Callahan A, Goldstein LB, Hennerici M, Sillesen H, Rudolph A, Welch MA; SPARCL Investigators. Crimmins D,....., **Minagar A**, De Bastos M. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack. Neurology. 2009;72:688-94. Epub 2008 Sep 3.
138. Geurts JJ, Stys PK, **Minagar A**, Amor S, Zivadinov R. Gray matter pathology in (chronic) MS: Modern views on an early observation. J Neurol Sci. 2009 Feb 25.
139. Harris MK, Shneyder N, Borazanci A, Korniychuk E, Kelley RE, **Minagar A**. Movement disorders. Med Clin North Am. 2009;93(2):371-388.
140. Kelley RE, **Minagar A**. Memory complaints and dementia. Med Clin North Am. 2009;93(2):389-406.
141. Zivadinov R, **Minagar A**. Evidence for gray matter pathology in multiple sclerosis: A neuroimaging approach. J Neurol Sci. 2009 Apr 2. [Epub ahead of print]
142. Kernan WN, Viscoli CM, Demarco D, Mendes B, Shrauger K, Schindler JL, McVeety JC, Sicklick A, Moalli D, Greco P, Bravata DM, Eisen S, Resor L, Sena K, Story D, Brass LM, Furie KL, Gutmann L, Hinnau E, Gorman M, Lovejoy AM, Inzucchi SE, Young LH, Horwitz RI; IRIS Trial Investigators. Adams HP, Coull BM, Furie K, Peduzzi PN, Guarino PD, Schwartz G, Spence D, Tanne D, Walker MD, Buse JB, Chambless L, Faxon D, Pary JK, Dunes D, Halsey J, Zweifler R, Lopez I, Palestrant D, Lansberg M, Albers G, Verro P, Warwick T, Nguyen L, Ovbiagele B, Meyer B, Johnston S, Hughes R, Silverman I, Schindler J, Albakri E, Silliman S, Kelly M, Singleton L, Kramer J, Wang D, Pedelty L, Fleck J, Jacoby M, Leira E, Wallace R, Ehtisham A, Pettigrew L, **Minagar A**, Sigsbee B, Wityk R, Kumar S, Kase C, Furie K, Mitsias P, Majid A, Nassief A, Hsu C, Fayad P, Lukovits T, Clark R, Graham G, Fonzetti P, Volpe B, Salgado M, Burgin W, Sundararajan S, Katzan I, Hanna J, Slivka A, Kleindorfer D, Tietjen G, Clark W, Diamond B, Tayal A, Friday G, Gentile N, Bell R, Uchino K, Vora N, Santiago F, Feldmann E, Easton J, O'Duffy A, Ling J, Hart R, Johnson M, Skalabrini E, Gorman M,

- Solenski N, Johnston K, Geraghty M, Dromerick A, Torbey M, Winder T, Shuaib A, Penn A, Malik S, Sher F, Chan R, Spence J, Bayer N, Mackey A, Verreault S, Durocher A, Lebrun L, Berger L, Boulanger J, Minuk J, Cote R. Boosting enrollment in neurology trials with Local Identification and Outreach Networks (LIONS). *Neurology*. 2009;72(15):1345-51.
143. Fadil H, Borazanci A, Ait Ben Haddou E, Yahyaoui M, Korniychuk E, Jaffe SL, **Minagar A**. Chapter 13 early onset dementia. *Int Rev Neurobiol*. 2009;84:245-262.
144. **Minagar A**. Preface. *Int Rev Neurobiol*. 2009;84:xv-xvi.
145. Gurwra S, Hailey B, Thompson A, **Minagar A**, Hardjasudarma M, Gonzalez-Toledo E. Volumetric Examination of MS plaques and correlation with EDSS ratings. *The J Neuroradiology* 2009; 22: 151-153.
146. Shapshak P, Somboonwit C, Drumright LN, Frost SD, Commins D, Tellinghuisen TL, Scott WK, Duncan R, McCoy C, Page JB, Giunta B, Fernandez F, Singer E, Levine A, **Minagar A**, Oluwadara O, Kotila T, Chiappelli F, Sinnott JT. Molecular and contextual markers of hepatitis C virus and drug abuse. *Mol Diagn Ther*. 2009;13:153-179.
147. Stosic M, Ambrus J, Garg N, Weinstock-Guttman B, Ramanathan M, Kalman B, **Minagar A**, Munschauer FE, Galey TM, Hussein S, Bakshi R, Zivadinov R. MRI characteristics of patients with antiphospholipid syndrome and multiple sclerosis. *J Neurol*. 2009 Jul 26. [Epub ahead of print].
148. Horstman LL, Jy W, Bidot CJ, Nordberg ML, **Minagar A**, Alexander JS, Kelley RE, Ahn YS. Potential roles of cell-derived microparticles in ischemic brain disease. *Neurol Res*. 2009 Oct;31(8):799-806.
149. **Minagar A**, Kelley RE. Translation of stroke research into stroke therapy. *Neurol Res*. 2009 Oct;31(8):773-774.
150. O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T; for the BEYOND Study Group. 250 mug or 500 mug interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. *Lancet Neurol*. 2009 Oct;8(10):889-897. **BEYOND study group investigators:**
O Abramsky, A Achiron, M Agius, F Aichner, H Altenkirch, MP Amato, B Anten, T Arbizu, P Ash, C Ballario, K Bashir, K Baum, U Baumhackl, G Beaver, A Belova, J Berger, T Berger, P Berlit, W Beuche, V Bhan, K Bigley, V Bissay, C Blake, L Bo, A Boyko, B Brochet, M Brown, D Callegaro, A Carra, W Carroll, M Cascione, S Christie, M Clanet, P Clavelou, V L Clementino, C Confavreux, J Cooper, A Cross, A Csanyi, A Czlonkowska, M D'Hooghe, P Damier, M Debouverie, G Defer, T Demina, N Deri, R Diem, A Dressel, B Dubois, P Dunne, P Duquette, L Durelli, G Edan, S Elias, I Elovaara, F Esfahani, S Evtushenko, T H Fabijan, O Fernandez, M L B Ferreira, A Fink, S Flechter, C Ford, C Francesconi, M Freedman, W Fryze, A Gabbai, G Gacs, P Gallo, S Gazda, C Gerloff, S Glyman, A Goodman, M Gottesman, F Grand'Maison, J Guarnaccia, A Gutierrez, J Haas, H J Hansen, O Hardiman, R Heard, F Heidenreich, J Herbert, R Herminia Scola, S Hodgkinson, F Hoffmann, R Holub, J Huddleston, B Hughes, M Hughes, S Hunter, B Hurwitz, G Izquierdo, E Jacobasch, F Jacques, G Jakab, P Jongen, C Karageorgiou, A Karni, L Kasper, M Kaufman, M Keidel, B Khatri, R Kiefer, S Kirzinger,

M Kita, S Komoly, S Kotov, W Kozubski, E Kumlien, H Kwiecinski, P Labouge, C LaGanke, Y Lapierre, C Lebrun-Frenay, T Leist, SA Leon, G Luetic, S Lynch, T Lynch, N Malkova, M Maltezou, C Markowitz, C Martin, H Mattle, D Mattson, M Metra, U Meyding-Lamade, R Milo, I Milonas, A Miller, T Miller, **A Minagar**, ...G Comi.

151. Pachner AR, Warth JD, Pace A, Goelz S; INSIGHT investigators. Bashi K, Cascione M, Cohen B, Garwacki D, Goodin D, Huddlestone J, Hughes B, Hunter S, Hutton G, Kirzinger S, LaGanke C, LaGanke JP, Lucas S, Mikol D, **Minagar A**, Mitchell G, Moses H, Parks BJ, Pachner A, Rammohan K, Reder A, Rizvi S, Simsarian J, Singer B, Stevens J, van den Noort S, Vollmer T, Wray S. Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study. *Neurology*. 2009;73(18):1493-500.
152. Weller RO, Galea I, Carare RO, **Minagar A**. Pathophysiology of the lymphatic drainage of the central nervous system: Implications for pathogenesis and therapy of multiple sclerosis. *Pathophysiology*. 2009 Nov 30.
153. **Minagar A**, Fowler M, Harris MK, Jaffe SL. Neurologic presentations of systemic vasculitides. *Neurol Clin*. 2010;28(1):171-84.
154. Harris MK, Elliott D, Schwendimann RN, **Minagar A**, Jaffe SL. Neurologic presentations of hepatic disease. *Neurol Clin*. 2010;28(1):89-105.
155. **Minagar A**. Preface. *Neurol Clin*. 2010;28(1):xiii-xiv.
156. Maghzi A, Ghazavi H, Ahsan M, Etemadifar M, Mousavi S, Khorvash F, **Minagar A**. Increasing female preponderance of multiple sclerosis in Isfahan, Iran: a population-based study. *Mult Scler*. 2010;16(3):359-61.
157. Horstman LL, Jy W, Ahn YS, Zivadinov R, Maghzi AH, Etemadifar M, Alexander JS, **Minagar A**. Role of platelets in neuroinflammation: a wide-angle perspective. *J Neuroinflammation*. 2010;7(1):10.
158. **Minagar A**, Alexander JS, Sahraian MA, Zivadinov R. Alemtuzumab and multiple sclerosis: therapeutic application. *Expert Opin Biol Ther*. 2010;10(3):421-9.
159. Poorjavad M, Derakhshandeh F, Etemadifar M, Soleymani B, **Minagar A**, Maghzi AH. Oropharyngeal dysphagia in multiple sclerosis. *Mult Scler*. 2010;16(3):362-5.
160. Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O'Neill, Neyer L, Sheridan J, Wang C, Fong A, Rose JW; CHOICE investigators. Collaborators (57) Jacques F, Melanson M, Kremenchutzky M, Lapierre Y, O'Connor P, Blevins G, Wadinger K, Sommer N, Heesen C, Pozzilli C, Gallo P, Comi G, Arbizu T, Fernandez O, Montalban X, Casanova B, Garcia-Moreno A, Absher J, Cooper J, Khatri B, Fox E, Wynn D, Picone M, Herbert J, Lynch S, **Minagar A**, Carter J, Sullivan H, Martin J, Ford C, Phillips T, Kasper L, Dunn J, English J, Steingo B, Edwards K, Honeycutt W, Jacobs A, Kaufman M, Freedman M, Pugh S, Vollmer T, Thomas F, Pirko I, Markowitz C, Rose J, Storey J, Jeffery D, Kahn O, Dickson R, Gottesman M, Miller DE, Reingold SC, Cutter G, Wolinsky J, Freedman MS, Edan G. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. *Lancet Neurol*. 2010;9(4):381-90.

161. **Minagar A**. Ischemic Stroke. BMJ Point-of Care 2010.
162. Carrubba S, **Minagar A**, Gonzalez-Toledo E, Chesson AL Jr, Frilot C 2nd, Marino AA. Multiple sclerosis impairs ability to detect abrupt appearance of a subliminal stimulus. *Neurol Res.* 2010;32(3):297-302.
163. Nourbakhsh A, Vannemreddy P, **Minagar A**, Toledo EG, Palacios E, Nanda A. Hydatid disease of the central nervous system: a review of literature with an emphasis on Latin American countries. *Neurol Res.* 2010;32(3):245-51.
164. **Minagar A**, Zivadinov R. Pathophysiology of demyelinating disorders. *Pathophysiology.* 2010 May 12.
165. Ramasamy DP, Ramanathan M, Cox JL, Antulov R, Weinstock-Guttman B, Bergsland N, Benedict RH, Dwyer MG, **Minagar A**, Zivadinov R. Effect of Met66 allele of the BDNF rs6265 SNP on regional gray matter volumes in patients with multiple sclerosis: A voxel-based morphometry study. *Pathophysiology.* 2010 May 15
166. Patterson II J, **Minagar A**, Natarajan N, Takalkar A. Alzheimer's disease detection with objective statistical evaluation of FDG-PET brain scans: essential methodology for early identification. *Future Neurol.* (2010) 5(2), 259–276.
167. Alexander J, Harris M, Wells S, Mills G, Chalamidas K, Ganta V, McGee J, Jennings M, Gonzalez-Toledo E, **Minagar A**. Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon- β 1b. *Mult Scler.* 2010;16(7):801-809.
168. Alexander JS, Zivadinov R, Maghzi AH, Ganta VC, Harris MK, **Minagar A**. Multiple sclerosis and cerebral endothelial dysfunction: Mechanisms. *Pathophysiology.* 2010 Jul 19. [Epub ahead of print]
169. Veluswamy H, Suryawala K, Sheth A, Salvatierra E, Wells SR, Painter A, Chaitanya GV, Manas K, Baig K, Zwank E, Boktor M, Cromer WE, Mathis JM, Datti B, Jordan PA, **Minagar A** and Alexander JS. African-American Inflammatory Bowel Disease in a Southern U.S. Health Center. *BMC Gastroenterology* In press 2010.
170. Chaitanya GV, Franks SE, Cromer W, Wells SR, Bienkowska M, Jennings MH, Ruddell A, Ando T, Wang Y, Gu Y, Sapp M, Mathis JM, Jordan PA, **Minagar A**, Alexander JS. Differential cytokine responses in human and mouse lymphatic endothelial cells to cytokines in vitro. *Lymphat Res Biol.* 2010;8:155-64.
171. Shneyder N, Harris MK, **Minagar A**. Movement disorders in patients with multiple sclerosis. *Handb Clin Neurol.* 2011;100:307-14.
172. Editorial neuroAIDS review. *AIDS.* 2011 Jan 14;25(2):123-41. Shapshak P, Kanguane P, Fujimura RK, Commins D, Chiappelli F, Singer E, Levine AJ, **Minagar A**, Novembre FJ, Somboonwit C, Nath A, Sinnott JT.
173. Sahraian MA, Maghzi AH, Etemadifar M, Minagar A. Dalfampridine: review of its efficacy in improving gait in patients with multiple sclerosis.

J CNS Diseases.

174. Lowery-Nordberg M, Eaton E, Gonzalez-Toledo E, Harris MK, Chalamidas K, McGee-Brown J, Ganta CV, **Minagar A**, Cousineau D, Alexander JS. The effects of high dose interferon-beta1a on plasma microparticles: Correlation with MRI parameters. *J Neuroinflammation*. 2011 May 9;8(1):43.
175. Poloni G, **Minagar A**, Haacke EM, Zivadinov R. Recent developments in imaging of multiple sclerosis. *Neurologist*. 2011 Jul;17(4):185-204.
176. Vasheghani-Farahani A, Sahraian MA, Darabi L, Aghsaie A, **Minagar A**. Incidence of various cardiac arrhythmias and conduction disturbances due to high dose intravenous methylprednisolone in patients with multiple sclerosis. *J Neurol Sci*. 2011 Aug 8.
177. Horstman LL, Jy W, Ahn YS, Maghzi AH, Etemadifar M, Alexander JS, McGee JC, **Minagar A**. Complement in neurobiology. *Front Biosci*. 2011 Jun1;17:2921-60.
178. Mohajeri M, Farazmand A, Mohyeddin Bonab M, Nikbin B, **Minagar A**. FOXP3 Gene Expression in Multiple Sclerosis Patients Pre- and Post Mesenchymal Stem Cell Therapy. *Iran J Allergy Asthma Immunol*. 2011 Sep;10(3):155-61.
179. Maghzi AH, Etemadifar M, Heshmat-Ghahdarijani K, Nonahal S, **Minagar A**, Moradi V. Cesarean delivery may increase the risk of multiple sclerosis. *Mult Scler*. 2011 Oct 7.
180. Chaitanya GV, Cromer W, Wells S, Jennings M, Mathis J, **Minagar A**, Alexander J. Metabolic modulation of cytokine-induced brain endothelial adhesion molecule expression. *Microcirculation*. 2011 Oct 8. doi: 10.1111/j.1549-8719.2011.00141.x.
181. Etemadifar M, Mollabashi M, Chitsaz A, Behnamfar O, Bahrami E, **Minagar A**, Maghzi AH. Seroprevalence of NMO-IgG among patients with neuromyelitis optica and opticospinal multiple sclerosis. *Clin Neurol Neurosurg*. 2011 Oct 17.
182. Chaitanya GV, Cromer WE, Wells SR, Jennings MH, Couraud PO, Romero IA, Weksler B, Erdreich-Epstein A, Mathis JM, **Minagar A**, Alexander JS. Gliovascular and cytokine interactions modulate brain endothelial barrier in vitro. *J Neuroinflammation*. 2011 Nov 23;8(1):162.
183. Sahraian MA, Radue EW, Eshaghi A, Besliu S, **Minagar A**. Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis. *Eur J Neurol*. 2011 Dec 5.
184. Maghzi AH, Etemadifar M, Heshmat-Ghahdarijani K, Moradi V, Nonahal S, Ghorbani A, **Minagar A**. Cigarette Smoking and the Risk of Multiple Sclerosis: A Sibling Case-Control Study in Isfahan, Iran. *Neuroepidemiology*. 2011 Dec 7;37(3-4):238-242.
185. Shapshak P, Duncan R, Margarita Duran E, Farinetti F, **Minagar A**, Rodriguez H, Francesco Chiappelli F, Kanguane P, Levine AJ, Singer E, Somboonwit C, Sinnott JT. Gene expression for HIV-associated dementia and HIV encephalitis in microdissected neurons 1: preliminary analysis. *Neurobehavioral HIV Medicine* 2011;3 1-26.
186. Haghjooy Javanmard S, Saadatnia M, Homayouni V, Nikoogoftar M, Maghzi AH, Etemadifar M, Chaitanya GV, McGee JC, **Minagar A**, Alexander JS. Interferon-beta-1b

- protects against multiple sclerosis-induced endothelial cells apoptosis. *Front Biosci (EliteEd)*. 2012 Jan 1;4:1368-74.
187. Zivadinov R, Hussein S, Bergsland N, **Minagar A**, Dwyer MG Magnetization transfer imaging of acute black holes in patients on glatiramer acetate. *Front Biosci (Elite Ed)*. 2012 Jan 1;4:1496-504.
188. **Minagar A**, Rabinstein AA Neurologic emergencies. *Neurol Clin*. 2012 Feb;30(1):xiii-xiv. No abstract available.
189. **Minagar A**, Rabinstein AA, Rezania K, Sih M, Alekseeva N, Petrea RE, Alhajeri A, Nick ST, Gonzalez-Toledo E, Sahraian MA, Kelley RE. Neurologic emergencies: case studies. *Neurol Clin*. 2012 Feb;30(1):345-56.
190. Alekseeva N, Geller F, Patterson J, Fitz-Gerald M, Horton R, **Minagar A**. Urgent and emergent psychiatric disorders. *Neurol Clin*. 2012 Feb;30(1):321-44.
191. Carrubba S, **Minagar A**, Jr AL, Ii CF, Marino AA. Increased determinism in brain electrical activity occurs in association with multiple sclerosis. *Neurol Res*. 2012 Mar 20
192. Shunichi Homma, MD, et al. Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm. *NEJM* 2012
Supplementary Appendix of contributors: United States, LSU Health Sciences Center (66): **A. Minagar**, R. Kelley, J. McGee.
193. McCarthy P, Scott LK, Ganta CV, **Minagar A**. Hypothermic protection in traumatic brain injury. *Pathophysiology*. 2012 May 22.
194. Martinez NE, Sato F, Omura S, **Minagar A**, Alexander JS, Tsunoda I. Immunopathological patterns from EAE and Theiler's virus infection: Is multiple sclerosis a homogenous 1-stage or heterogenous 2-stage disease? *Pathophysiology*. 2012 May 25.
195. **Minagar A**, Ma W, Zhang X, Wang X, Zhang K, Alexander JS, Gonzalez-Toledo E, Albitar M. Plasma Ubiquitin-Proteasome System Profile in patients with Multiple Sclerosis: Correlation with clinical features, neuroimaging and treatment with interferon- β 1b. *Neurological Research* 2012
196. Faridar A, Eskandari G, Sahraian MA, **Minagar A**, Azimi A. Vitamin D and multiple sclerosis: a critical review and recommendations on treatment. *Acta Neurol Belg*. 2012 Jul 6. [Epub ahead of print]
197. Gaitour E, Talebzadeh Nick S, Roberts C, Gonzalez-Toledo E, Munjampalli S, **Minagar A**, Vrooman B, Souzalnitski D, Zamanifekri B. Glossopharyngeal neuralgia secondary to vascular compression in a patient with multiple sclerosis: a case report. *J Med Case Rep*. 2012 Jul 19;6(1):213. [Epub ahead of print]
198. **Minagar A**, Maghzi AH, McGee JC, Alexander JS. Emerging roles of endothelial cells in multiple sclerosis pathophysiology and therapy. *Neurol Res*. 2012 Jul 23

199. Maghzi AH, **Minagar A**. Urinary tract infection in multiple sclerosis: a practical algorithm for a common problem. *Eur J Neurol*. 2012
200. Talebzadeh Nick S, Roberts C, Billiodeaux S, Elliott Davis D, Zamanifekri B, Sahraian MA, Alekseeva N, Munjampalli S, Roberts J, **Minagar A**. Multiple sclerosis and pain. *Neurol Res* 2012
201. Zivadinov R, Ramanathan M, Ambrus J, Hussein S, Ramasamy DP, Dwyer MG, Bergsland N, **Minagar A**, Weinstock-Guttman B. Anti-phospholipid antibodies are associated with response to interferon-beta 1a treatment in MS: results from a 3-year longitudinal study. *Neurol Res*. 2012;34(8):761-9.
202. Zivadinov R, Alexander SJ, **Minagar A**. Vascular pathology of multiple sclerosis. *Neurol Res*. 2012;34(8):735-7.
203. Karmon Y, Ramanathan M, **Minagar A**, Zivadinov R, Weinstock-Guttman B. Arterial, venous and other vascular risk factors in multiple sclerosis. *Neurol Res*. 2012;34(8):754-60.
204. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Vigiotta V, Dawson KT; CONFIRM Study Investigators. Fox RJ, Phillips J, ..., **Minagar A**, Rammohan K, Gottesman M, Schaeffer J, Carlini W, Stein L, Buckler R, Azizi S, Bauer B, Ford C. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. *N Engl J Med*. 2012;367(12):1087-97.
205. Etemadifar M, Abtahi SH, **Minagar A**, Akbari M, Masaeli A, Tabrizi N. Late-onset Multiple Sclerosis in Isfahan, Iran. *Arch Iran Med*. 2012;15(10):596-8.
206. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA; for the CARE-MS I investigators. **The Lancet Supplementary index for the CARE-MS investigators:** **Alireza Minagar, MD**, Louisiana State University Health Sciences Center, Shreveport, LA
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. **Lancet**. 2012 Oct 31. doi:pii: S0140-6736(12)61769-3.
207. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators. **Alireza Minagar, MD**, Louisiana State University Health Sciences Center, Shreveport, LA

- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. **Lancet**. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.
208. Maghzi AH, Sahraian MA, Shaygannejad V, **Minagar A**. Is the Iranian Revolution to Blame for the Increasing Incidence of Multiple Sclerosis in Iran? *Neuroepidemiology* 2013;40:68–69.
209. **Minagar A**, Rabinstein AA. The human spinal cord. Preface. *Neurol Clin*. 2013;31(1):xiii-xiv.
210. Sahraian MA, Radue EW, **Minagar A**. Neuromyelitis optica: clinical manifestations and neuroimaging features. *Neurol Clin*. 2013;31(1):139-52.
211. Bican O, **Minagar A**, Pruitt AA. The spinal cord: a review of functional neuroanatomy. *Neurol Clin*. 2013;31(1):1-18.
212. Derakhshandi H, Etemadifar M, Feizi A, Abtahi SH, **Minagar A**, Abtahi MA, Abtahi ZA, Dehghani A, Sajjadi S, Tabrizi N. Preventive effect of vitamin D3 supplementation on conversion of optic neuritis to clinically definite multiple sclerosis: a double blind, randomized, placebo-controlled pilot clinical trial. *Acta Neurol Belg*. 2012 Dec 19.
213. Hagemeyer J, Weinstock-Guttman B, Heininen-Brown M, Poloni GU, Bergsland N, Schirda C, Magnano CR, Kennedy C, Carl E, Dwyer MG, **Minagar A**, Zivadinov R. Gray matter SWI-filtered phase and atrophy are linked to disability in MS. *Front Biosci (Elite Ed)*. 2013;5:525-32.
214. **Minagar A**, Barnett MH, Benedict RH, Pelletier D, Pirko I, Sahraian MA, Frohman E, Zivadinov R. The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects. *Neurology*. 2013;80(2):210-9.
215. Mortazavi M, Moeinzadeh F, Saadatnia M, Shahidi S, McGee JC, **Minagar A**. Effect of Magnesium Supplementation on Carotid Intima-Media Thickness and Flow-Mediated Dilatation among Hemodialysis Patients: A Double-Blind, Randomized, Placebo-Controlled Trial. *Eur Neurol*. 2013;69(5):309-316.
216. Chaitanya GV, Cromer WE, Parker CP, Couraud PO, Romero IA, Weksler B, Mathis JM, **Minagar A**, Alexander JS. A Recombinant Inhibitory Isoform of Vascular Endothelial Growth Factor_{164/165} Aggravates Ischemic Brain Damage in a Mouse Model of Focal Cerebral Ischemia. *Am J Pathol*. 2013 Jul 29. doi:pii: S0002-9440(13)00422-7. 10.1016/j.ajpath.2013.06.009.
217. Maghzi AH, **Minagar A**, Waubant E. Neuroprotection in Multiple Sclerosis: A Therapeutic Approach. *CNS Drugs*. 2013 Aug 17. [Epub ahead of print]
218. Chaitanya GV, Omura S, Sato F, Martinez NE, **Minagar A**, Ramanathan M, Guttman BW, Zivadinov R, Tsunoda I, Alexander JS. Inflammation induces neuro-lymphatic protein expression in multiple sclerosis brain neurovasculature. *J Neuroinflammation*. 2013 Oct 14;10(1):125.

219. Sahraian MA, Moghadasi AN, Owji M, Maboudi M, Kosari F, McGee JC, **Minagar A**. Cutaneous and pulmonary sarcoidosis following treatment of multiple sclerosis with interferon-beta-1b: a case report. *J Med Case Rep*. 2013 Dec 13;7(1):270. [Epub ahead of print].
220. **Minagar A**. Current and future therapies for multiple sclerosis. *Scientifica (Cairo)*. 2013;2013:249101.
221. Alexander JS, Prouty L, Tsunoda I, Ganta CV, **Minagar A**. Venous endothelial injury in central nervous system diseases. *BMC Med*. 2013 Oct 11;11:219. doi: 10.1186/1741-7015-11-219.
222. Martinez NE, Karlsson F, Sato F, Kawai E, Omura S, **Minagar A**, Grisham MB, Tsunoda I. Protective and Detrimental Roles for Regulatory T Cells in a Viral Model for Multiple Sclerosis. *Brain Pathol*. 2014 Jan 14.
223. Chaitanya GV, **Minagar A**, Alexander JS. Neuronal and astrocytic interactions modulate brain endothelial properties during metabolic stresses of in vitro cerebral ischemia. *Cell Commun Signal*. 2014 Jan 17;12:7.
224. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. HR; Bapineuzumab 301 and 302 Clinical Trial Investigators, **Minagar A**. *N Engl J Med*. 2014 Jan 23;370(4):322-33.
225. McGee J, Maghzi AH, **Minagar A**. Neurophobia: A global and under-recognized phenomenon. *Clin Neurol Neurosurg*. 2014 Mar 27.
226. Maghzi AH, **Minagar A**. IL1- β expression in multiple sclerosis. *J Neurol Sci*. 2014 Aug 15;343(1-2):1.
227. Noroozian M, Azadfar P, Akbari L, Sadeghi A, Houshmand M, Vousooghi N, Zarrindast MR, **Minagar A**. Early-Onset Alzheimer's Disease in Two Iranian Families: A Genetic Study. *Dement Geriatr Cogn Disord*. 2014;38(5-6):330-336.
228. Fakharzadeh S, Sahraian MA, Hafizi M, Kalanaky S, Masoumi Z, Mahdavi M, Kamalian N, **Minagar A**, Nazaran MH. The therapeutic effects of MSc1 nanocomplex, synthesized by nanochelating technology, on experimental autoimmune encephalomyelitic C57/BL6 mice. *Int J Nanomedicine*. 2014;9:3841-53.
229. McGee J, **Minagar A**. Utilization of brain MRI with focus on cerebral lesions and atrophy to better characterize MS phenotypes. *J Neurol Sci*. 2014 Sep 6. pii:
230. Naghshineh H, Shahin D, Sahraian MA, **Minagar A**. Co-existence of neurofibromatosis type 2 and multiple sclerosis: A case report. *Mult Scler Relat Disord*. 2014 May;3(3):384-6. doi: 10.1016/j.msard.2013.08.008. Epub 2013 Nov 7.

231. **Minagar A**, Rabinstein AA. Cerebellar diseases. Preface. *Neurol Clin*. 2014 Nov;32(4):xiii-xiv. doi: 10.1016/j.ncl.2014.09.001. Epub 2014 Oct 24. No abstract available.
232. Toxic-metabolic, nutritional, and medicinal-induced disorders of cerebellum. Alekseeva N, McGee J, Kelley RE, Maghzi AH, Gonzalez-Toledo E, **Minagar A**. *Neurol Clin*. **2014** Nov;32(4):901-11. doi: 10.1016/j.ncl.2014.07.001. Epub **2014** Sep 11. Review.
233. Javalkar V, Kelley RE, Gonzalez-Toledo E, McGee J, **Minagar A**. Acute ataxias: differential diagnosis and treatment approach. *Neurol Clin*. 2014 Nov;32(4):881-91. doi: 10.1016/j.ncl.2014.07.004. Epub 2014 Oct 24. Review.
234. Roostaei T, Nazeri A, Sahraian MA, **Minagar A**. The human cerebellum: a review of physiologic neuroanatomy. *Neurol Clin*. 2014 Nov;32(4):859-69. doi: 10.1016/j.ncl.2014.07.013. Epub 2014 Oct 24. Review.
235. Pullicino PM, Qian M, Sacco RL, Freudenberger R, Graham S, Teerlink JR, Mann D, Di Tullio MR, Ponikowski P, Lok DJ, Anker SD, Lip GY, Estol CJ, Levin B, Mohr JP, Thompson JL, Homma S; WARCEF Investigators, **Minagar A**. Recurrent stroke in the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial. *Cerebrovasc Dis*. 2014;38(3):176-81. doi: 10.1159/000365502. Epub 2014 Oct 9.
236. McGee J, **Minagar A**. Co-existence of tumefactive MS and hepatitis C: A need for further screening and new therapeutic challenge. *J Neurol Sci*. **2015** Feb 15;349(1-2):1-2. doi: 10.1016/j.jns.2014.12.033. Epub **2015** Jan 3. No abstract available.
237. Heerfordt's Syndrome: An interesting and under-recognised manifestation of sarcoidosis. McGee J, **Minagar A**. *Sultan Qaboos Univ Med J*. **2015** Feb;15(1):e7-8. Epub **2015** Jan 21. No abstract available.
238. Miller DH, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Kita M, Wheeler-Kingshott CA, Tozer DJ, MacManus DG, Yousry TA, Goodsell M, Yang M, Zhang R, Vignietta V, Dawson KT; CONFIRM study investigators, **Minagar A**. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. *Neurology*. **2015** Mar 17;84(11):1145-52. doi: 10.1212/WNL.0000000000001360. Epub **2015**
239. Homma S, Thompson JL, Qian M, Ye S, Di Tullio MR, Lip GY, Mann DL, Sacco RL, Levin B, Pullicino PM, Freudenberger RS, Teerlink JR, Graham S, Mohr JP, Labovitz AJ, Buchsbaum R, Estol CJ, Lok DJ, Ponikowski P, Anker SD; WARCEF Investigators **Minagar A**. Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy. *Circ Heart Fail*. **2015** May;8(3):504-9. doi: 10.1161/CIRCHEARTFAILURE.114.001725. Epub **2015** Apr 7.
240. MR imaging and cognitive impairment in MS: a neuroimaging-based mechanistic view. McGee J, **Minagar A**. *Clin Neurol Neurosurg*. **2015** May;132:52-3. doi: 10.1016/j.clineuro.2015.02.010. Epub **2015** Feb 23. No abstract
241. Sahraian MA, Moghadasi AN, Owji M, Naghshineh H, **Minagar A**. Neuromyelitis optica with linear enhancement of corpus callosum in brain magnetic resonance imaging with contrast: a case report. *J Med Case Rep*. **2015** Jun 10;9:137. doi: 10.1186/s13256-015-0613-9.
242. Alexander JS, Chervenak R, Weinstock-Guttman B, Tsunoda I, Ramanathan M, Martinez N, Omura S, Sato F, Chaitanya GV, **Minagar A**, McGee J, Jennings MH, Monceaux C, Becker F, Cvek U, Trutschl M, Zivadinov R. Blood circulating microparticle species in relapsing-remitting and secondary progressive multiple sclerosis. A case-control, cross sectional study with conventional

- MRI and advanced iron content imaging outcomes. *J Neurol Sci.* **2015** Aug 15;355(1-2):84-9. doi: 10.1016/j.jns.2015.05.027. Epub **2015** May 28.
243. McGee J, **Minagar A**. Thalamus and MS: Role of thalamic atrophy in daily living and employment activities of MS patients. *J Neurol Sci.* 2015 Sep 4.
244. **Minagar A**, Finney GR, Heilman KM. Neurobehavioral Manifestations of Neurological Diseases: Diagnosis and Treatment. *Neurol Clin.* 2016 Feb;34(1):xiii-xiv.
245. McGee J, Alekseeva N, Chernyshev O, **Minagar A**. Traumatic Brain Injury and Behavior: A Practical Approach. *Neurol Clin.* 2016;34(1):55-68.
246. Moghadasi AN, Pourmand S, Sharifian M, **Minagar A**, Sahraian MA. Behavioral Neurology of Multiple Sclerosis and Autoimmune Encephalopathies. *Neurol Clin.* 2016;34(1):17-31.
247. Finney GR, **Minagar A**, Heilman KM. Assessment of Mental Status. *Neurol Clin.* 2016;34(1):1-16.
248. Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams HP Jr, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O'Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR; IRIS Trial Investigators **Alireza Minagar**. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. *N Engl J Med.* 2016 Apr 7;374(14):1321-31. doi: 10.1056/NEJMoa1506930. Epub 2016 Feb 17.
249. Eskandarieh S, Heydarpour P, **Minagar A**, Pourmand S, Sahraian MA. Multiple Sclerosis Epidemiology in East Asia, South East Asia and South Asia: A Systematic Review. *Neuroepidemiology.* 2016;46(3):209-21. doi: 10.1159/000444019. Epub 2016 Feb 19.
250. Navalkele DD, Barlinn K, **Minagar A**, Chernyshev OY. Exploration of screening practices for obstructive sleep apnea in stroke medical community: A pilot study. *Pathophysiology.* 2016 Jun;23(2):105-9. doi: 10.1016/j.pathophys.2016.04.001. Epub 2016 Apr 13.
251. Sharma K, Kalakoti P, Shaughnessy JE, De La Cruz N, Dossani RH, Zhu P, Gonzalez-Toledo E, Ledbetter C, Pinskiotn JB, Nanda A, Riel-Romero RM, **Minagar A**, Notarianni C, Sun H. Psammomatous Cavernous Malformation Presenting as Drug Resistant Epilepsy: Case Illustration and Review of Literature. *World Neurosurg.* 2016 Jun 6. pii: S1878-8750(16)30367-9. doi: 10.1016/j.wneu.2016.05.093. [Epub ahead of print] Review. No abstract available.
252. Sharma K, **Minagar A**, Sun H. Proton Pump Inhibitors and Dementia Incidence. *JAMA Neurol.* 2016 Jun 20.
253. Nasr Z, Majed M, Rostami A, Sahraian MA, **Minagar A**, Amini A, McGee JC, Etemadifar M. Prevalence of multiple sclerosis in Iranian emigrants: review of the evidence. *Neurol Sci.* 2016 Jun 28.
254. Fox RJ, Chan A, Gold R¹, Phillips JT, Selmaj K, Chang I, Novas M, Rana J¹, Marantz JL. Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: Patient management considerations. *Neurol Clin Pract.* 2016 Jun;6(3):220-229. Authors and investigators: Zdeněk Ambler, Edvard Ehler, ..., **Alireza Minagar**,and Tarek Youstry.
255. Yun JW, Xiao A, Tsunoda I, **Minagar A**, Alexander JS. From trash to treasure: The untapped potential of endothelial microparticles in neurovascular diseases. *Pathophysiology.* 2016 Aug 12. pii

256. Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators **Minagar A**. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. *Neurology*. 2016 Nov 8;87(19):1985-1992. Epub 2016 Oct 12.
257. White LA, Stevenson EV, Yun JW, Eshaq R, Harris NR, Mills DK, **Minagar A**, Couraud PO, Alexander JS. The Assembly and Application of 'Shear Rings': A Novel Endothelial Model for Orbital, Unidirectional and Periodic Fluid Flow and Shear Stress. *J Vis Exp*. 2016 Oct 31;(116). doi: 10.3791/54632.
258. Lee RH, Couto E Silva A, Lerner FM, Wilkins CS, Valido SE, Klein DD, Wu CY, Neumann JT, Della-Morte D, Koslow SH, **Minagar A**, Lin HW. Interruption of perivascular sympathetic nerves of cerebral arteries offers neuroprotection against ischemia. *Am J Physiol Heart Circ Physiol*. 2017 Jan 1;312(1):H182-H188. doi: 10.1152/ajpheart.00482.2016. Epub 2016 Nov 18.
259. Maghzi H, Shaygannejad V, **Minagar A**, Hassanzadeh A, Maghzi AH. Consanguinity and multiple sclerosis susceptibility: A case control study. *Mult Scler Relat Disord*. 2016 Nov;10:179-180. doi: 10.1016/j.msard.2016.09.013. Epub 2016 Sep 30.
260. Bir SC, Nanda A, Cuellar H, Sun H, Guthikonda B, Liendo C, **Minagar A**, Chernyshev OY. Coexistence of obstructive sleep apnea worsens the overall outcome of intracranial aneurysm: a pioneer study. *J Neurosurg*. 2017 Mar 21:1-12. doi: 10.3171/2016.10.JNS162316. [Epub ahead of print]
261. McGee JC, **Minagar A**. Study of SOCS gene family expression profile in MS patients: Another step forward. *J Neurol Sci*. 2017 Apr 15;375:479-480. doi: 10.1016/j.jns.2017.02.016. Epub 2017 Feb 16. No abstract available.
262. Bir SC, Nanda A, Patra DP, Maiti TK, Liendo C, **Minagar A**, Chernyshev OY. Atypical presentation and outcome of cervicogenic headache in patients with cervical degenerative disease: A single-center experience. *Clin Neurol Neurosurg*. 2017 May 13;159:62-69. doi: 10.1016/j.clineuro.2017.05.016. [Epub ahead of print]
263. Bir SC, Patra DP, Maiti TK, Bollam P, **Minagar A**, Nanda A. Direct Comparison of Gamma Knife Radiosurgery and Microsurgery for Small Size Meningiomas. *World Neurosurg*. 2017 May;101:170-179. doi: 10.1016/j.wneu.2017.01.105. Epub 2017 Feb 6.
264. Connor DE Jr, Chaitanya GV, Chittiboina P, McCarthy P, Scott LK, Schrott L, **Minagar A**, Nanda A, Alexander JS. Variations in the cerebrospinal fluid proteome following traumatic brain injury and subarachnoid hemorrhage. *Pathophysiology*. 2017 May 13. pii: S0928-4680(16)30062-1. doi: 10.1016/j.pathophys.2017.04.003. [Epub ahead of print]
265. Schwendimann RN, **Minagar A**. Liver Disease and Neurology. *Continuum (Minneapolis, Minn)*. 2017 Jun;23(3, Neurology of Systemic Disease):762-777.
266. Chernyshev OY, Bir SC, Maiti TK, Patra DP, Liendo C, Cuellar H, **Minagar A**, Nanda A. Changing paradigm in the management of elderly patients with intracranial aneurysms: An institutional review. *J Clin Neurosci*. 2017 Jun 6. pii: S0967-5868(17)30282-5. doi: 10.1016/j.jocn.2017.05.015.

267. Jakimovski D, Weinstock-Guttman B, Ramanathan M, Kolb C, Hojnacki D, **Minagar A**, Zivadinov R. Ocrelizumab: a B-cell depleting therapy for multiple sclerosis. *Expert Opin Biol Ther.* 2017 Sep;17(9):1163-1172. doi: 10.1080/14712598.2017.1347632. Epub 2017 Jul 3. Review.

268. Epstein KA, Viscoli CM, Spence JD, Young LH, Inzucchi SE, Gorman M, Gerstenhaber B, Guarino PD, Dixit A, Furie KL, Kernan WN; IRIS Trial Investigators, **Minagar A**. Smoking cessation and outcome after ischemic stroke or TIA. *Neurology.* 2017 Oct 17;89(16):1723-1729. doi: 10.1212/WNL.0000000000004524. Epub 2017 Sep 8.

269. Chernyshev OY, Bir SC, Maiti TK, Patra DP, Sun H, Guthikonda B, Liendo C, Cuellar H, **Minagar A**, Nanda A. The Relationship Between Obstructive Sleep Apnea and Ruptured Intracranial Aneurysms. *J Clin Sleep Med.* 2017 Oct 18. pii: jc-17-00061. [Epub ahead of print]

270. McGee JC, **Minagar A**. Assessing the cerebral gray matter volume in response to fingolimod therapy in multiple sclerosis: A more analytic view. *J Neurol Sci.* 2017 Dec 15;383:230-231. doi: 10.1016/j.jns.2017.10.018. Epub 2017 Oct 13. No abstract available.

271. McGee JC, **Minagar A**. A case of neuromyelitis optica spectrum disorder presenting with undiagnosed Sjogren's syndrome and a single, atypical tumefactive lesion: A diagnostic challenge. *J Neurol Sci.* 2017 Dec 15;383:219-220. doi: 10.1016/j.jns.2017.10.042. Epub 2017 Nov 1. No abstract available.

271. Bir SC, Konar SK, Patra DP, Maiti TK, **Minagar A**, Nanda A. Management of a complex intracranial arteriovenous malformation with gamma knife radiosurgery: A case report with review of literature. *J Clin Neurosci.* 2017 Dec 13. pii: S0967-5868(17)31217-1.

272. Wu CYC, Lerner FM, Couto E Silva A, Possoit HE, Hsieh TH, Neumann JT, **Minagar A**, Lin HW, Lee RHC. Utilizing the Modified T-Maze to Assess Functional Memory Outcomes After Cardiac Arrest. *J Vis Exp.* 2018 Jan 5;(131). doi: 10.3791/56694.

273. Omura S, Sato F, Martinez NE, Range T, Ekshyyan L, **Minagar A**, Alexander JS, Tsunoda I. Immunoregulation of Theiler's virus-induced demyelinating disease by glatiramer acetate without suppression of antiviral immune responses. *Arch Virol.* 2018 Jan 23. doi: 10.1007/s00705-018-3729-6. [Epub ahead of print]

274. **Minagar A**, Alexander JS. Cervical spinal cord atrophy impact on quality of life in MS: A neuroimaging study. *J Neurol Sci.* 2019 Jun 15;401:101-102. doi: 10.1016/j.jns.2019.04.022. [Epub 2019 Apr 17].

275. Couto E Silva A, Wu CY, Citadin CT, Clemons GA, Possoit HE, Grames MS, Lien CF, **Minagar A**, Lee RH, Frankel A, Lin HW. Protein arginine methyltransferases in cardiovascular and neuronal function. *Mol Neurobiol.* 2020 Mar;57(3):1716-1732. doi: 10.1007/s12035-019-01850-z. [Epub 2019 Dec 10].

276. Chernyshev OY, Bir SC, Maiti TK, Patra DP, Sun H, Guthikonda B, Kelley RE, Cuellar H, **Minagar A**, Nanda A.
The relationship between obstructive sleep apnea and ruptured intracranial aneurysms.
J Clin Sleep Med. 2019 Dec 15;15(12):1839-1848. doi: 10.5664/jcsm.8096.
277. Yun JW, Barzegar M, Boyer CJ, **Minagar A**, Couraud PO, Alexander JS.
Brain endothelial cells release apical and basolateral microparticles in response to inflammatory cytokine stimulation: Relevance to neuroinflammatory stress?
Front Immunol. 2019 Jun 27;10:1455. doi: 10.3389/fimmu.2019.01455. [eCollection 2019].
278. Omura S, Sato F, Martinez NE, Park AM, Fujita M, Kennett NJ, Cvek U, **Minagar A**, Alexander JS, Tsunoda I.
Bioinformatics analyses determined the distinct CNS and peripheral surrogate biomarker candidates between two mouse models for progressive multiple sclerosis.
Front Immunol. 2019 Mar 19;10:516. doi: 10.3389/fimmu.2019.00516. [eCollection 2019].
279. Yun JW, Cvek U, Kilgore PCSR, Tsunoda I, Omura S, Sato F, Zivadinov R, Ramanathan M, **Minagar A**, Alexander JS.
Neurolymphatic biomarkers of brain endothelial inflammatory activation: Implications for multiple sclerosis diagnosis.
Life Sci. 2019 Jul 15;229:116-123. doi: 10.1016/j.lfs.2019.05.021. [Epub 2019 May 10].
280. Couto E Silva A, Wu CY, Citadin CT, Clemons GA, Possoit HE, Grames MS, Lien CF, **Minagar A**, Lee RH, Frankel A, Lin HW.
Protein arginine methyltransferases in cardiovascular and neuronal function.
Mol Neurobiol. 2020 Mar;57(3):1716-1732. doi: 10.1007/s12035-019-01850-z. [Epub 2019 Dec 10].
281. Wu CYC, Lopez-Toledano MA, Daak AA, Clemons GA, Citadin CT, Sancilio FD, Rabinowicz AL, **Minagar A**, Neumann JT, Lee RHC, Lin HW.
SC411 treatment can enhance survival in a mouse model of sickle cell disease.
Prostaglandins Leukot Essent Fatty Acids. 2020 Jul;158:102110. doi: 10.1016/j.plefa.2020.102110. [Epub 2020 May 3].
282. Barzegar M, Wang Y, Eshaq RS, Yun JW, Boyer CJ, Cananzi SG, White LA, Chernyshev O, Kelley RE, **Minagar A**, Stokes KY, Lu XH, Alexander JS.
Human placental mesenchymal stem cells improve stroke outcomes via extracellular vesicles-mediated preservation of cerebral blood flow.
EBioMedicine. 2021 Jan;63:103161. doi: 10.1016/j.ebiom.2020.103161. [Epub 2020 Dec 19].
283. Cananzi SG, White LA, Barzegar M, Boyer CJ, Chernyshev OY, Yun JW, Kelley RE, Almendros I, **Minagar A**, Farré R, Alexander JS.
Obstructive sleep apnea intensifies stroke severity following middle cerebral artery occlusion.
Sleep Med. 2020 Mar;67:278-285. doi: 10.1016/j.sleep.2020.01.014. [Epub 2020 Jan 29].
284. Schrott L, Yi P, Jackson K, Jackson GS, Webb C, **Minagar A**, Yun JW, Purdum G, Rios DJ, Tyler TA, Vizcaino MI, Castor JL, Castor T, Alexander JS.
Nanoparticle-encapsulated bryostatins-1 activates α -secretase and PKC isoforms in vitro and facilitates acquisition and retention of spatial learning in an Alzheimer's disease mouse model.
Curr Alzheimer Res. 2020;17(14):1302-1310. doi: 10.2174/1567205018666210218155835.
285. Barzegar M, Wang Y, Eshaq RS, Yun JW, Boyer CJ, Cananzi SG, White LA, Chernyshev O, Kelley RE, **Minagar A**, Stokes KY, Lu XH, Alexander JS.
Human placental mesenchymal stem cells improve stroke outcomes via extracellular vesicles-mediated

preservation of cerebral blood flow.

EBioMedicine. 2021 Jan;63:103161. doi: 10.1016/j.ebiom.2020.103161. [Epub 2020 Dec 19].

286. Zamanifekri B, Zamanifekri M, Babakoochi S, Whalen M, Minagar A. Leptomeningeal metastatic prostate cancer imitating a subdural hematoma. *Cureus*. 2022 Nov 11;14(11):e31380. doi: 10.7759/cureus.31380. [eCollection 2022 Nov].

287. Minagar A, Jabbour R.

Published erratum: *Correction to: The human gut microbiota: a dynamic biologic factory*. *Adv Biochem Eng Biotechnol*. 2025;189:243. doi: 10.1007/10_2024_253.

Abstracts (selected from more than 300)

1. Shulman LM, Minagar A, Weiner WJ. The tolerability and efficacy of pramipexole in patients with idiopathic Parkinson's disease previously on bromocriptine, pergolide, or cabergoline. *American Academy of Neurology* 1998;P05.046.
2. Weiner WJ, Minagar A, Shulman LM. Pramipexole in progressive supranuclear palsy. *American Academy of Neurology* 1998;PO6.046.
3. Weiner WJ, Minagar A, Shulman LM. Olanzapine for the treatment of hallucinations and delusions in Parkinson's disease. 5th International Congress of Parkinson's disease and Movement disorders. *Movement Disorders* 1998;S2:1.169, 62.
4. Shulman LM, Minagar A, Weiner WJ. Pramipexole in atypical parkinsonism. Fifth International Congress of Parkinson's disease and Movement disorders. *Movement Disorders* 1998;S2:1.168, 62.
5. Weiner WJ, Minagar A, Shulman LM. Olanzapine for the treatment of hallucinations and delusions in Parkinson's disease. Symposia on etiology, pathogenesis, and treatment of Parkinson's disease and Huntington's disease. Canada 1998.
6. Minagar A, Sheremata WA. Devic's disease: A therapeutic challenge. Consortium of Multiple Sclerosis Centers 1998.
7. Strasser S, Minagar A, DeToledo JC, Lowe MR, Ramsay RE. Electrographic focal discharges changing to bilateral bisynchronous generalized EEG patterns after administration of lidocaine. *American Clinical Neurophysiology Society*, 1998:C122.

8. Patterson-Lake M, Minagar A. Cocaine induced parkinsonism. American Neurological Association, Canada 1998.
9. Weiner WJ, Minagar A, Shulman LM. Ropinirole after pramipexole failure in advanced Parkinson's disease. American Neurological Association, Canada 1998.
10. Sheremata WA, Minagar A. Reduction of relapses in multiple sclerosis after Natalizumab (Antegren) treatment. Annals of Neurology (Suppl 1) 1998;507.
11. Sheremata WA, Minagar A, Jy W, Ahn YS. Alterations of platelet CD62 expression by interferon B1a (IFNB1a) treatment in multiple sclerosis. American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 1998.
12. Minagar A, DeTeledo JC, Lowe MR, Ramsay RE. Persisting aphasia as the sole manifestation of partial status epilepticus. American Clinical Neurophysiology Society, 1998:C123.
13. Strasser S, Minagar A, DeToledo JC. Cortical-subcortical MRI/CT lesions in reversible posterior leukoencephalopathy syndrome (RPLS): encephalopathy or seizure? Annals of Neurology 1999;46:472.
14. Shulman LM, Minagar A, Rabinstein A, Weiner WJ. The use of dopamine agonists in very elderly patients with Parkinson's disease. Annals of Neurology (Suppl) 1999;46:498.
15. Shulman LM, Wen X, Weiner WJ, Bateman D, Perez MA, Minagar A, Duncan R, Konefal J. Acupuncture (ACUPX) therapy for the symptoms of Parkinson's disease (PD). Symposia on Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders Seattle 1999.
16. Marcos J, Minagar A. Amyloidoma of the nervous system without systemic amyloidosis: report of two cases and review of literature. American Association of Neurological Surgeons, Louisiana 1999.
17. Minagar A, Sheremata WA. Betaseron and cerebral infarctions. Consortium of multiple sclerosis centers 1999.
18. Minagar A, Sheremata WA. Multiple sclerosis and brain tumors. Consortium of multiple sclerosis centers 1999.
19. Lotfi J, Ghaemmaghami AB, Minagar A, Weiner WJ. Avicenna and his description of trigeminal neuralgia. American Academy of Neurology, San Diego 2000.
20. Tusa RJ, Minagar A, Sheremata WA. Perverted vestibular nystagmus and multiple sclerosis. Annals of Neurology 2000;48:474.
21. Sevush S, Minagar A, Peruyera G, Brizel S. Ventricular dilatation on MRI predicts early onset of urinary incontinence in patients with Alzheimer's disease. Annals of Neurology 2000;48:429.
22. Minagar A, Jy W, Jimenez JJ, Mauro LM, Horstman L, Sheremata WA, Ahn YS. Endothelial microparticles in multiple sclerosis, as defined by expression of PECAM-1, are elevated in exacerbation: A new aspect of disease pathogenesis. Annals of Neurology 2000;48:475.
23. Shulman LM, Minagar A, Rabinstein A, Weiner WJ. The use of dopamine agonists in aging with Parkinson's disease. Annals of Neurology 2000;48:466.
24. Shulman LM, Rabinstein A, Minagar A, Weiner WJ. Patient's access to information: Parkinson's disease and the Internet. International symposium of Parkinson's disease and movement disorders. Barcelona, Spain 2000.

25. Gass C, Whitney J, Minagar A, Kuljis RO. Crossed Wernicke's aphasia in a patient with neurosyphilis. International Neuropsychology Meeting Orlando, Florida 2000.
26. Minagar A, Jy W, Jimenez JJ, Mauro LM, Horstman L, Sheremata WA, Ahn YS. Plasma from MS patients in exacerbation induces release of PECAM-1 positive endothelial microparticles (EMP) from cultured microvascular endothelial cells. International Society for Neuroscience Meeting New Orleans, Louisiana 2000.
27. Shapshak P, Minagar A, Bradley WG. Microglia and astrocytes in HIV-associated dementia, Alzheimer's disease, and multiple sclerosis. Scientific Meeting and Poster Session. Department of Psychiatry and Behavioral Sciences. University of Miami 2000.
28. Ahn YS, Jy W, Jimenez JJ, Horstman LL, Pastor J, Minagar A, Mauro LM, Mao WW. Laboratory detection of endothelial injury in occlusive vascular and neurological disorders: Assay of endothelial microparticles. Biotechnology Berlin, Germany 2000. Volume 3; section IV:38:110-112.
29. Minagar A, Jy W, Jimenez JJ, Mauro LM, Horstman LL, Mao WW, Sheremata WA, Ahn YS. Increased endothelial microparticles (EMP) and platelet activation in multiple sclerosis (MS) in exacerbation and presence of factor in MS plasma inducing EMP generation in vitro. Blood 2000;96:43a.
30. Sheremata WA, Minagar A, Whiteman M, Onufer J. Interferon-alfa-n3 (Alferon N) Reduces Gadolinium Enhancing Brain Lesions in Multiple Sclerosis. World Federation of Neurologists. London England 2001.
31. Minagar A, Shapshak P, Heyes M, Sheremata WA, Fujimara R, Ownby R, Goodkin K, and Eisdorfer K. MICROGLIA AND ASTROCYTES IN NEURO-AIDS, ALZHEIMER'S DISEASE, AND MULTIPLE SCLEROSIS. Miami International Biotechnology Meeting, Miami, Florida 2001.
32. Shapshak P, Duncan R, Minagar A, Goodkin K. Cytokines in The HIV-1 Infected Brain: IFN- γ Shows A Greater Response Than IL-4 or TNF- α . (Platform presentation) American Academy of Neurology (AAN) 2001. Neurology Suppl (3) 2001; (S63) 476.
33. Minagar A, Dai AI, Ghaemmaghami AB, Ragheb J. Rahzes and his description of pupillary light reaction and theory of conditioned reflexes. American Academy of Neurology (AAN) 2001.
34. Sheremata WA, Onufer J, Whiteman M, Minagar A, Quencer R. Interferon AN3 reduces MRI gadolinium enhancement in MS patients. International Congress of MS Centers Australia 2001.
35. Onufer J, Whiteman M, Minagar A, Quencer R, Sheremata WA. Response of MR T2 lesion load in patients with multiple sclerosis: A blinded study of treatment with interferon β 1b (Betaseron) versus Interferon α -3 (Alferon N) versus untreated patients. Annals of Neurology (Suppl 1) 2001;S28.
36. Minagar A, Jy W, Jimenez JJ, Sheremata WA, Mauro LM, Horstman LL, Ahn YS. Elevated blood monocytes-endothelial microparticles in multiple sclerosis. Annals of Neurology (Suppl 1) 2001;S27 .
37. Sheremata WA, Whiteman M, Onufer J, Minagar A, Quencer R. Alferon (IFN-alfa-n3) and Betaseron (IFN-beta-1b) reduce T2 lesion load in multiple sclerosis (MS): A blind MRI study of 75 patients.ECTRIMS 2001.
38. Shapshak P, Duncan R, Kuljis R, Minagar A, Alcabes P, Fujimura R, Stewart R, Rodriguez de la Vega P, Goodkin K, and Petito CK. Drug abuse and AIDS brain: Unexpected expression of neuronal nitric oxide synthase, IFN- γ , TNF- α , & IL-4. 63rd Annual Scientific Meeting of the College of Problems of Drug Dependence, Scottsdale, AZ, June 16th-June 23rd, 2001.

39. Sharp C, Jawahar A, Sasaki M, Minagar A, Elrod J, Nanda A, Alexander JS. Expression of endothelial cell adhesion molecules (ECAM) on human brain endothelial cells in response to γ -knife treatment. The Annual Meeting of the Congress of Neurological Surgeons, Philadelphia, September 2002.
40. Minagar A, Ostanin D, Sasaki M, Jennings M, Elrod J, Sharp C, Xiao F, Wang Y, Kelley RE, Alexander JS. Disintegration of cerebral endothelial junctional structural by serum factors from multiple sclerosis patients. *Annals of Neurology* October 2002; Supplement: S39.
41. Sharp CD, Warren A, Long A, Nanda A, Minagar A, Jawahar A, Elrod JW, Jennings MH and Alexander JS. Glutamate causes an NMDAR1-dependent intracellular ROS production, tyrosine phosphorylation and disruption of zonula occludin (ZO-1). Annual Meeting of Oxygen Society, San Antonio Texas 2002.
42. Jy W, Jimenez JJ, Minagar A, Mauro L, Horstman LL, Bidot CJ, Sheremata WA, Ahn YS. Endothelial microparticles (EMP) enhance adhesion and transmigration of monocytes: EMP-monocyte conjugates as a marker of disease activity in multiple sclerosis (MS). *Blood* 100(11,part 1):460a, 2002.
43. Shapshak P, Duncan R, Torres-Munoz JE, Keegan M, Minagar A, and Petitto CK. PRELIMINARY GENE EXPRESSION STUDIES: AIDS VS. CONTROL BRAINS, DRUG ABUSE, PROBLEMS AND SOLUTIONS. Proc. 2nd Virt. Conf. Genom. and Bioinformatics North Dakota State University, USA, 2002.
44. Sharp CD, Jackson TH, Houghton J, Warren A, Nanda A, Minagar A, Alexander J S. Glutamate causes an NMDAR1 and Kainate receptor dependent intracellular ROS production in human cerebral endothelial cells. *Experimental Biology* San Diego, CA 2003.
45. Sharp CD, Warren A, Jackson TH, Minagar A, Jennings M, Alexander JS. Cytochalasin-D (an actin filament destabilizer) causes a matrix metalloproteinase dependent decrease in endothelial barrier function. *Experimental Biology* San Diego, CA 2003.
46. Patterson JC II, Tainter KH, Lilien DL, Glabus MF and Minagar A. Discrimination of patients with early cognitive changes with negative PET scan readings by objective statistical comparison to a standard derived from a control database. *American Academy of Neurology* Hawaii 2003.
47. Minagar A, Grazia Clemente M, Kelley RE, Alexander JS, and Fasano A. Elevated serum zonulin and multiple sclerosis: a potential modulator of endothelial tight junctions. *American Academy of Neurology* Hawaii 2003 PO3.119.
48. James C Patterson JC II, Glabus MF, Tainter KH, Lilien DL, Minagar A. Changes in Brain Metabolism in Patients with Early Cognitive Changes and Negative PET Clinical Results. Presented at the 9th International Conference on Functional Mapping of the Human Brain, June 19-22, 2003. New York, NY. Available on CD ROM in *Neuroimage*, Vol 19, No 2. 2003.
49. Sharp CD, Warren AC, Jennings M, Nanda A, Kelley RE, Alexander JS, Minagar A. Role of NMDA receptors in cerebral transendothelial migration of neutrophils. *American Neurological Association* San Francisco 2003.
50. Leskov I, Minagar A, Ghafourifar P. Reactive nitrogen/oxygen are elevated in multiple sclerosis. The Society for Neuroscience (SFN), The Shreveport chapter Abstract 27. Shreveport, LA May 2, 2003.
51. JY W, Delgado S, Minagar A, Ahn Y, Sheremata W. William A. Sheremata; Interferon- β 1a Reduces Plasma CD31+Endothelial Microparticles in MS. *Ann Neurol* 2003;54:S60.

52. Elrod J, Long A, Carpenter A, Jennings M, Minagar A, Alexander JS. Effects of IFN- β 1b on tight junctional proteins and barrier integrity induced by IFN- γ : Role in multiple sclerosis. Experimental Biology Meeting Washington DC 2004.
53. Jimenez JJ, Jy W, Mauro LM, Ahn YS, Minagar A. Interferon B-1b inhibits transendothelial migration of monocyte-endothelial microparticle complexes associated with multiple sclerosis. Neurology Supplement (5) 2004;62:7:P05.061.
54. Carpenter AC, Elrod JW, Jennings M, Minagar A, Alexander JS. Activation of endothelial PKC reduces PECAM spatial distribution: a suggestive role for reduced neutrophil migration. Experimental Biology Meeting Washington DC 2004.
55. Shapshak P, Duncan R, Minagar A, Goodkin K, Duran EM, Nath A, Turchan J, Davis W, Seth R, Kazic T. "A Decade of Neuroscience Informatics: Looking Ahead" Bioinformatics and Gene expression in NeuroAIDS.(NIMH 10th Annual Human Brain Project Conference). April 26th - 27th 2004 @ NIH.
56. Minagar A, Shapshak P, Duran EM, Kablinger A, Alexander JS, Kelley RE, Seth R, and Kazic T. Gene expression in neurologic and psychiatric disorders: HIV-Associated Dementia, Alzheimer's disease, Multiple Sclerosis, and Schizophrenia. 8th World Multiconference on Systemics, Cybernetics and Informatics (SCI 2004).
57. Shapshak P, Goodkin K, Duncan R, ², Nath A, Turchan J, Davis W, Duran EM, Ziegler F, Minagar A, Seth R, Kazic T. GENE EXPRESSION IN HUMAN NEURONS IN CULTURE AND BRAIN. USE OF DIFFERING MICROARRAY AND BIOINFORMATICS TECHNOLOGIES. 11th Society for Neuroimmune Pharmacology CONFERENCE CLEARWATER BEACH, FLORIDA, April 6-10, 2005.
58. Bidot CJ, Jy W, Jimenez JJ, Horstman LL, Ahn YS, Minagar A. Antiphospholipid antibodies in multiple sclerosis are exclusively IgM class, and occur predominately in exacerbations. AAN 2005 Miami, FL
59. Gonzalez-Toledo E, Hardjasudarma M, Minagar A, Kelley RE. Role of diffusion weighted imaging (DWI) in characterization of acute demyelinating lesions of relapsing-remitting multiple sclerosis. American Roentgen Ray Society 2005
60. Murray TJ, Minagar A, Aichner FT for the PROOF Study Investigators. Efficacy and tolerability of intramuscular interferon-beta-1a compared with subcutaneous interferon-beta-1a in relapsing multiple sclerosis: results from PROOF. Presented at the 15th Meeting of the European Neurological Society, June 18-22, 2005, Vienna, Austria. Abstract P 419.
61. Bergsland N, Dwyer M, Stosic M, Sharma J, Nussenbaum F, Durfee J, Hani N, Abdelrahman N, Jaisani Z, Minagar A, Hoque R, Munschauer F, Zivadinov R. Use of Perfusion- and Diffusion-Weighted Imaging in Differential Diagnosis of Acute and Chronic Ischemic and Demyelinating Lesions. (Poster at American Academy of Neurology Chicago USA 2008. Neurology Supplement 2008;70(Suppl. 1) **P08.183 A474**
62. Dwyer MG, Bergsland N, Saluste E, Sharma J, Jaisani Z, Durfee J, Abdelrahman N, Minagar A, Hoque R, Munschauer F, Zivadinov R. Application of Hidden Markov Random Field (HMRF) Approach for Quantification of Perfusion/Diffusion Mismatch in Acute Ischemic Stroke (Platform presentation at American Academy of Neurology Chicago USA 2008. Neurology Supplement 2008;70(Suppl. 1) **IN5-2.005**

63. Martinez, NE, Karlsson, F, Sato F, Omura S, Minagar A, Grisham MB, and Tsunoda I. (2011). Regulatory T cells play contrasting roles in a viral model for multiple sclerosis. The American Neurological Association (ANA) 136th Annual Meeting, September 25-27, 2011, San Diego, California. *Ann Neurol* **70** (Suppl 15): S90-1.

Letters to the Editor/ Reply from Authors to Letters to the Editor

Koeffler M, Minagar A, David NJ. Bilateral infarction in the territory of anterior cerebral arteries. *Neurology* 2000;54:538.

Quinn N, Minagar A, Shulman LM, Weiner WJ. Transderm induced psychosis in a patient with Parkinson's disease. *Neurology* 2000;54:1877.

Swerdloff MA, Tarras SC, Shulman LM, Minagar A, Sharma K, Weiner WJ. Amantadine induced peripheral neuropathy. *Neurology* 2000;55:460-461.

Fernandez HH, Weiner WJ, Minagar A, Shulman LM. Quetiapine for L-dopa-induced psychosis in PD. *Neurology*. 2000;55(6):899.

Burneo JG, Papamitaki NIH, Panayiotis MD, Minagar A. Cerebral ventricles are smaller in Hispanic than non-Hispanic patients with Alzheimer's disease. *Neurology* 2001;56:139-140.

Translated Books to Persian (Farsi)

1. V.I. Serinivas, MD. Acute Abdominal Disorders.1980
Translated by Minagar A. 1986.
2. George D. Zuidema, MD. Johns Hopkins Atlas of Human Functional Anatomy. 1986
Translated by: Minagar A, Ghassemi M, Behzad F, Mostofi B. 1987
3. Etemadi H, Maleknejad P, Minagar A. Basic Medical Bacteriology 1987
4. N.J.T. Fitzgerald MD, PhD, DSA. Neuroanatomy, Basic and Applied. 1988
Minagar A, Vosugh Azad J. 1990
5. Jurgan Thorwald. The Century of Surgeon 1945.
Minagar A. 1992
6. Plum F, Posner J. Coma and Stupor. 1991
Translated by: Minagar A. 1992
7. Neumayer Anton. Dictators in the Mirror of Medicine
Translated by: Minagar A 2001
7. Howard L. Weiner, MD. Curing MS: How Science Is Solving the Mysteries of Multiple Sclerosis 2005
Translated by: Alireza Minagar, Masoud Etemadifar, Amir Hadi Maghzi
Published by Isfahan University of Medical Sciences 2011

Edited Books

1. **Inflammatory Disorders of Nervous System**
Editors: Alireza Minagar and J. Steven Alexander
Humana Press 2005
2. **NeuroAIDS**
Editors: Alireza Minagar and Paul Shapshak
Nova Scientific Publisher 2006
3. **International Review of Neurobiology of Multiple Sclerosis 2007**
Alireza Minagar
Elsevier
4. **International Review of Neurobiology of “Dementia” 2009**
Alireza Minagar
Elsevier
5. **Neurologic Clinics of North America**
Special Issue: Neurology and Systemic Disease
Alireza Minagar 2010
Elsevier
6. **Neurological Disorders and Pregnancy**
Alireza Minagar
Elsevier
2010
7. **Neuroinflammation**
Alireza Minagar
Elsevier
2010
8. **Neurologic Clinics of North America**
Special Issue: Neurologic Emergencies
Alireza Minagar and Alejandro A. Rabinstein 2012
Elsevier
9. **Neurologic Clinics of North America**
Special Issue: Spinal cord diseases
Alireza Minagar and Alejandro A. Rabinstein 2013
Elsevier
10. **Neurologic Clinics of North America**
Special Issue: Cerebellar Disease
Alireza Minagar and Alejandro A. Rabinstein 2014
Elsevier
11. **Multiple sclerosis: An overview of clinical features, pathophysiology, neuroimaging, and treatment options**
Edited by: Alireza Minagar

Published in 2014

By: Morgan and Claypool Life Sciences, Inc.

12. Handedness: A Window to Explore the Neuroscience of Brain Lateralization

Edited by: Maryam Noroozian, Alireza Minagar, Sara Khalaj

Published in 2014

By: Nova Science Pub Inc.

13. Multiple sclerosis: A mechanistic view

Textbook by: Alireza Minagar

2015

Elsevier

14. Neurologic Clinics of North America

Special Issue: Neurobehavioral Manifestations of Neurological Diseases: Diagnosis & Treatment

Edited by: Alireza Minagar, Glen Finney, and Kenneth M. Heilman 2016

Elsevier

15. Inflammatory Disorders of Nervous System

Editors: Alireza Minagar and J. Steven Alexander

Humana Press

2017 (Second edition)

Editorial responsibilities

Frontiers in Bioscience

Guest Managing Editors: Alireza Minagar and J. Steven Alexander

Special issue: Inflammatory disorders of the nervous system 2003 until and still open

Neurological Research

Guest Editor: Alireza Minagar

Special issue: Multiple sclerosis 2006

Member of the Editorial Board of Future Neurology since 2006

Member of the Editorial Board of Neurological Research since 2006

Member of the Editorial Board of “Alzheimer’s Disease Research Journal” since 2007

Guest Editor: International Review of Neurobiology-Special issue of Multiple Sclerosis 2007

Alireza Minagar

Elsevier

Neurological Research

Guest Editors: Alireza Minagar and Roger E. Kelley

Special issue: Vascular Neurology 2008

Many Publications

Guest Editor: International Review of Neurobiology-Special issue “Dementia” 2009

Alireza Minagar/ CV

Alireza Minagar

Elsevier

Guest Editors: Journal of Neurological Sciences-Special issue “Gray Matter Pathology in Multiple Sclerosis” 2009

Robert Zivadinov and Alireza Minagar

Guest Editors: Pathophysiology

Pathophysiology -Special issue “Demyelinating Disorders of Central Nervous System” 2010

Alireza Minagar and Robert Zivadinov

Elsevier

Guest Editor: Neurologic Clinics of North America 2010

Special Topic: “Neurologic Manifestations of Systemic Disease”

Alireza Minagar

2010

Elsevier

Associate Editor of BMC Neurology

2010-present

Alireza Minagar, MD, FAAN

Co-Editor in Chief

Neurology and Neurosurgery Year Book

2011, 2012, 2013

Elsevier

Guest Editors: Neurologic Clinics of North America 2012

Special Topic: “Neurologic Emergencies”

Alireza Minagar and Alejandro A. Rabinstein

2012

Elsevier

Guest Editors: Neurologic Clinics of North America 2013

Special Topic: “Spinal cord disease”

Alireza Minagar and Alejandro A. Rabinstein

2013

Elsevier

Guest Editors: Neurologic Clinics of North America 2013

Special Topic: “Cerebellar disease”

Alireza Minagar and Alejandro A. Rabinstein

2014

Elsevier

Multiple Sclerosis: An Overview of Clinical Features, Pathophysiology, Neuroimaging, and Treatment Options

Author: Alireza Minagar

Published by: Morgan and Claypool Life Sciences

Year of publication: 2014

Alireza Minagar/ CV

Handedness: A Window to Explore the Neuroscience of Brain Lateralization (Neuroscience Research Progress)

Authors: Maryam Noroozian, MD, Alireza Minagar, MD and Sara Khalaj, MD

Published by: Nova Science Pub Inc

Year of publication: 2014

Multiple sclerosis: A Mechanistic View

Author: Alireza Minagar

Published by: Elsevier 2016

Book Chapters

1. Sharkey-Mathis PK, Graybill JR, Minagar A
Infections of the Central Nervous System: Chronic Infection
Urgent and Emergent Neurology
Shulman LS, Weiner WJ 1999 PP 151-180
Lippincott-Williams-Wilkins Press

2. Minagar A, Shulman LM, Weiner WJ
Prognosis of Movement Disorders
In: Prognosis of Neurological Disorders
By: Evans RW, Baskin DS, Yatsu FM.
Oxford University Press 2000 PP 593-609
3. Minagar A, Koller WC
Torticollis (Cervical Dystonia)
Encyclopedia of the Neurological Sciences 2001
4. Minagar A, Lieberman A
Parkinson's Disease
The 2001 Americana Annual/Encyclopedia Year Book
5. Koller WC, Minagar A
Treatment strategies for the management of Parkinson's Disease.
In: Parkinson's Disease Management Guide. Physician Desk Reference (PDR)
2000; Section 1:101-130.
6. Minagar A, Koller WC
Huntington's Disease
In: Advances in Clinical Neurosciences
Editors: Sinha KK, Chandra P
Association of Neuroscientists of Eastern India 2001;11:259-267
7. Minagar A, Ghaemmaghami AM
Central Nervous System Vasculitis
In: Advances in Clinical Neurosciences
Editors: Sinha KK, Chandra P
Association of Neuroscientists of Eastern India 2001;11:299-313
8. Minagar A, Lieberman A.
Balance impairments in Parkinson's disease
The 2001 Americana Annual/Encyclopedia Year Book
9. Minagar A, Koller WC
Tremors: Kinetic and Static.
The Dana Guide to Brain Health and Disorders 2002
10. Minagar A
Neurological Complications of Rheumatoid Arthritis
In: Neurobase
By: Gilman Sid
Anchor Publications 2002 and 2003
11. Minagar A, Kelley RE
Acquired Cytomegalovirus Infection: Neurologic Complications
In: Neurobase
By: Gilman Sid
Anchor Publications 2002 and 2003
12. Minagar A, Kelley RE
Necrotizing Myelopathy (Lupus-related)
In: Neurobase
By: Gilman Sid

Anchor Publications 2002 and 2003

13. Minagar A, Kelley RE
Acquired Leptospirosis
In: Neurobase
By: Gilman Sid
Anchor Publications 2002 and 2003
14. Minagar A, and Alexander JS
Arnold Chiari malformation and syringomyelia
In: Saunders Manual of Neurologic Practice
By: Evans RW
W.B. Saunders 2003
15. Schwendimann RN, Minagar A, Kelley RE
Differential Diagnosis of Multiple Sclerosis
In: Advances in Clinical Neurosciences
Editors: Sinha KK, Chandra P
Association of Neuroscientists of Eastern India 2002;12:117-130
16. Minagar A, Kelley RE, Schwendimann RN
Stroke in Young Adults
In: Advances in Clinical Neurosciences
Editors: Sinha KK, Chandra P
Association of Neuroscientists of Eastern India 2002;12:219-234
17. Minagar A, Sheremata WA
Multiple Sclerosis and Demyelinating Disorders
In: Saunders Manual of Neurologic Practice
By: Evans RW
W.B. Saunders in press 2003
18. Minagar A, Shulman LM, Weiner WJ
Movement Disorders
In: Saunders Manual of Neurologic Practice
By: Evans RW
W.B. Saunders 2003
19. Koller WC, and Minagar A
Essential Tremor
In: Neurological Therapeutics 2003
By: John Noseworthy in press
Martin Dunitz Publications 2003
20. Minagar A, Benarroch EE, and Koller WC
Basic pharmacological principles and the blood-brain barrier
In: Neurological Therapeutics
By: John Noseworthy in press
Martin Dunitz Publications 2003
21. Koller WC, Minagar A, Lyons KE, Pahwa R
Surgical Treatment of Parkinson's Disease: Past, Present, and Future
In: Surgical Treatment of Parkinson's Disease
By: Daniel Tursy, MD, Jerrold Vitek, MD, Andres Lozano, MD
Humana Press 2003; pp 41-50.

21. Shapshak P, Crandall KA, Minagar A, Goodkin K, and Petito C, “**Integrating Models Of Neuropathogenesis in AIDS: Biological Constraints Of HIV Strains Related To Blood and Brain, HIV Load, Chemokines, Cytokines, and Nitric Oxide Synthase**” in “**The Spectrum of NeuroAIDS Disorders: Pathophysiology, Diagnosis, and Treatment**”, Editors, K Goodkin MD PhD, P Shapshak PhD, and W Bradley MD FRS (Cambridge University Press, Cambridge UK), *in press*, 2003.
22. Kelley RE, Minagar A.
Cerebrovascular Disease
In: Neurology for non-neurologist
By: Weiner WJ, Goetz CG
Lippincott Williams & Wilkins 2003
23. Elsharydah A, Minagar A, and Cork RC.
Advances in neuro-anesthesia
Advances in Clinical Neurosciences 2003;13:81-95
24. Jawahar A, Minagar A, Nanda A.
Stereotactic Radiosurgery using the Leksell Gamma Knife: Current Trends and Future Directives.
Advances in Clinical Neurosciences 2003;13:1-13
25. Minagar A, Shulman LM, Weiner WJ.
Multiple System Atrophy
In: Movement Disorders
By: Watts RL, Koller WC
McGraw Hill, New York, USA 2004
26. Kelley RE, Minagar A.
Neurological entities of posterior fossa
Neurosurgery of posterior fossa
By: Nanda A
2004
27. Minagar A, Gonzalez Toledo E, Alexander JS.
Central Nervous System Atrophy in Multiple Sclerosis: Mechanisms
Brain and Spinal Cord Atrophy
By: Robert Zivadinov and Rohit Bakshi
Nova
2004
28. Minagar A, Shapshak P, Alexander JS. **Pathogenesis of HIV associated dementia and multiple sclerosis: role of microglia and astrocytes.** In: The Role of Glia in Neurotoxicity, Second Edition, edited by Michael Aschner and Lucio G. Costa
CRC Press, Boca Raton, FL USA 2005
Chapter 16 pp 263-279.
29. Minagar A, Gonzalez-Toledo E, Kelley RE. **Role of magnetic resonance imaging in diagnosis and management of multiple sclerosis (Chapter IX).** In: Treatment and management of multiple sclerosis.
Frank Columbus
Nova Publications Hauppauge, NY 2005
Chapter IX pp 223-252
30. Minagar A and Alexander JS. **Endothelial cell-leukocyte interaction during CNS Inflammation.**
In: Inflammatory Disorders of Nervous System.

Editors: Minagar A and Alexander JS.
Humana Press, Totowa, NJ 2005

31. Jy W, Horstman LL, Jimenez JJ, Minagar A and Ahn YS. **Circulating Cell-Derived Microparticles in Thrombotic and Inflammatory Disorders**. In: Inflammatory Disorders of Nervous System. Editors: Minagar A and Alexander JS. Humana Press, Totowa, NJ 2005
32. Shapshak P, Minagar A, Duran EM, Ziegler F, Davis W, Seth R, and Kazic T. **Gene Expression in HIV-associated Dementia**. In: Inflammatory Disorders of Nervous System. Editors: Minagar A and Alexander JS. Humana Press, Totowa, NJ 2005
33. Shapshak P, Minagar A, Kanguane P, Frost S, Kosakovsky SL, Zarate PS, Singer E, Commins D, De Groot A, Quinones-Mateu M, Terwilliger E. **The Role of Viral Genetic Variability in HIV-Associated Neurocognitive Disorder. The Spectrum of Neuro-AIDS Disorders: Pathophysiology, Diagnosis, and Treatment PP: 201-219, 2008**
Editor: Karl Goodkin
AMS Press
33. **Neuropsychiatric Aspects of Prion Disease**
Minagar A, Alekseeva N, Shapshak P, Fernandez F.
Kaplan & Sadock's Comprehensive Textbook of Psychiatry, 9e 2009
33. **Neuropsychiatric Aspects of Prion Disease**
Minagar A, Alekseeva N, Shapshak P, Fernandez F.
Kaplan & Sadock's Comprehensive Textbook of Psychiatry, 10e 2016 in Press

List of Grants and Clinical Trials

Current Grants with NIH funding

Title: Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction Study (WARCEF) (NIH UO1 NS 39143 and UO1 NS 43975)

Source: NIH-NINDS

Number: (NIH UO1 NS 39143 and UO1 NS 43975)

Start Date: 1-1-2003

Role of Dr. Minagar: Co-Principal Investigator at LSUHSC-Neurology with Roger E. Kelley, MD

Co-workers: Roger E. Kelley, MD and Patricia Jinkins, MS

Title: African-American Antiplatelet Stroke Prevention Study (Secondary Stroke

Prevention Study in the African-American Community: Ticlopidine vs. Aspirin

(AAASPS) (NIH # 1R01-NS33430-01A1).

Source: NIH

Alireza Minagar/ CV

Number: NIH # 1R01-NS33430-01A1

Amount: \$ 180,000.00 (this is an ongoing study and we will receive more funding for this study)

Start and Terminal Date: two years at LSU (from 2001 until 2004)

Role of Dr. Minagar: Principal Investigator at Louisiana State University Health Sciences Center-Shreveport

Co-workers: Laura Warren, MS (Study coordinator)

Title: Soluble HLA molecules in patients with multiple sclerosis: Markers to predict and assess therapeutic response to Rebif (interferon beta-1a) (Independent Scientific Award/Grant)

Source: Serono-Pfizer

Amount: \$ 62,500.00

Start Date: 12-1-2003-1/1/2009

Role of Dr. Minagar: Principal Investigator

Co-workers: Irena Adamashvili, PhD, Roger E. Kelley, MD, Stephen L. Jaffe, MD, and Laura Warren, MS

An open-label trial of safety and efficacy of combination therapy with interferon- β -1a and oral doxycycline in patients with relapsing-remitting multiple sclerosis (Independent Scientific Award/Grant)

Source: Biogen-Idek

Number: This grant goes by its title

Amount: \$ 250,000.00

Start and Terminal Date: 1-1-2004 until 1-1-2008

Role of Dr. Minagar: Principal Investigator

Co-workers: J. Steven Alexander, PhD, and Laura Warren, MS

Structural/Functional (Proteomic) analysis of interactions between interferon-beta1b (Betaseron), cerebral endothelial cells, and matrix metalloproteinases (Independent Scientific Award/Grant)

Source: Bayer Pharmaceuticals (formerly known as Berlex Laboratories)

Number: This grant goes by its title

Amount: \$ 150,000.00

Start Date: 1-1-2004

Role of Dr. Minagar: Principal Investigator

Co-workers: J. Steven Alexander, PhD, and Laura Warren, MS

A Multicenter, Prospective and Retrospective, Long-Term Observational Study of AVONEX and Rebif to Determine the Efficacy, Tolerability, and Safety in Subjects with Relapsing Multiple Sclerosis (MS)

Source: Biogen-Idec

Number: This study is identified by its title

Amount: \$ 20,000.00 (this is an ongoing study and we will receive more funding for this study)

Start Date: 3-1-2003

Role of Dr. Minagar: Principal Investigator at LSUHSC-Neurology

Co-workers: Laura Warren, MS

Title of the project: Rebif (Interferon β -1a) lowers plasma levels of endothelial microparticles (EMP), monocyte-endothelial microparticles conjugates (M-EMP-Conjugates) and blocks transendothelial migration of M-EMP-Conjugates in patients relapsing-remitting multiple sclerosis

Source: Serono-Pfizer

Number: This study is identified by its title

Amount: \$ 79,500.00 (this is an ongoing study and we will receive more funding for this study)

Duration: 18 months

Role of Dr. Minagar: Principal Investigator

Alireza Minagar/ CV

Co-workers: J. Steven Alexander, PhD and Mary Lowery, PhD

Study Title: Insulin Resistance Intervention After Stroke Trial

Principal Investigator: Alireza Minagar, MD

Supported by: NIH-Yale University

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-
Remitting Multiple Sclerosis (CONFIRM)

Supported by: BiogenIdec

Principal Investigator: Alireza Minagar, MD

Educational Grants

Multiple Sclerosis Fellowship Award USD 50,000.00
Teva Neuroscience
2008

Multiple Sclerosis Fellowship Award USD 75,000.00
BiogenIdec
2009

Multiple Sclerosis Fellowship Award USD 50,000.00
Teva Neuroscience
2010

Multiple Sclerosis Fellowship Award USD 75,000.00
BiogenIdec
2010

Multiple sclerosis fellows whom I have trained:

Dr. Meghan K. Harris

Dr. Aimee Borazanci

Clinical Research Activities-Clinical Trials
Alireza Minagar, MD, FAAN
Certified Physician Investigator
As of January 2006

1. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild To Moderate Alzheimer's Disease Who Are Apolipoprotein Eε4 Carriers (Elan 302)
Role: Principal Investigator
2. A Multinational, Multicenter, Randomized, Parallel-Group Study Performed in Subjects with Relapsing-Remitting Multiple Sclerosis (RRS) to Assess the Efficacy, Safety, and Tolerability of Laquinimod over Placebo in a Double-Blind Design and of a Reference Arm of Interferon (Avonex) in a Rater-Blinded Design
Role: Principal Investigator
3. An international, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two year treatment with teriflunomide 7 mg once daily and 14 mg once daily versus placebo in patients with a first clinical episode suggestive of multiple sclerosis.
Role: Principal Investigator
4. A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif) in Treatment-Naïve Patients with Relapsing-Remitting Multiple Sclerosis
Role: Principal Investigator
5. A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patients with Relapsing-Remitting Multiple Sclerosis Who Have Relapsed On Therapy
Role: Principal Investigator
6. A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis (BG12)
Role: Principal Investigator
7. Insulin Resistance Intervention after Stroke Trial - IRIS - A randomized, placebo-controlled trial of pioglitazone, compared with placebo, for prevention of recurrent stroke and myocardial infarction after ischemic stroke (IND 64,622)
Role: Principal Investigator
8. CRESCENDO: Comprehensive Rimonabant Study of Cardiovascular ENDpoints and outcomes

Role: Principal Investigator

9. TYSABRI[®] Global Observational Program in Safety (TYGRIS)
Role: Principal Investigator
10. A Phase 3 multicenter, randomized, double-blind, parallel-group, placebo-controlled clinical study to determine the efficacy of BIIB017 in subjects with relapsing MS.
Role: Principal Investigator
11. A Multinational, Multicenter, Randomized, Parallel-Group Study Performed in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Laquinimod Over Placebo in a Double-blind Design and of a Reference Arm of Interferon β -1a (Avonex[®]), in a Rater-blinded Design.
Role: Principal Investigator
12. A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active-Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β -1a) to Natalizumab in Subjects with Relapsing-Remitting Multiple Sclerosis 101MS325 (SURPASS)
Role: Principal Investigator
13. JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri[®]: (STRATIFY-2)
Role: Principal Investigator
14. A multinational, multicenter, randomized, parallel group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of Glatiramer Acetate (GA) injection 40 mg administered three times a week compared to placebo in a double-blind design (GALA)
Role: Principal Investigator
15. MS090035 - "Plasma Endothelial Microparticles in Multiple Sclerosis: A Novel Metric Assay of Disease Activity and Response to Treatment"
Role: Sub-Investigator
16. Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF)
Role: Principal Investigator
17. ATAP: Alglucosidase Alfa Temporary Access Program
Role: Principal Investigator
18. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild To Moderate Alzheimer's Disease Who Are Apolipoprotein E ϵ 4 Non-Carriers (Elan 301)
Role: Principal Investigator

